[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 11702
1. Marcucci F, Mele A, Spada E, Candido A, Bianco E, Pulsoni A, Chionne P, Madonna E, Cotichini R, Barbui A, De Renzo A, Dore F, Iannitto E, Liso V, Martino B, Montanaro M, Pagano L, Musto P, Rapicetta M: High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica; 2006 Apr;91(4):554-7
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma.
  • In this hospital-based, multicenter case-control study we investigated the prevalence of hepatitis B virus (HBV)-related markers and HBV/hepatitis C virus (HCV) co-infection among B-cell non-Hodgkin's lymphoma (B-NHL) cases and controls.
  • The finding of a positive association between HBV infection and B-NHL raises the possibility that HBV may play an etiologic role in the induction of B-NHL.
  • [MeSH-major] Hepatitis B / complications. Lymphoma, B-Cell / virology

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16585021.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Hepatitis B Surface Antigens; 0 / Hepatitis C Antibodies
  •  go-up   go-down


2. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM: Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res; 2006 Oct 15;66(20):10145-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma.
  • The underlying mechanisms by which tumor cells are resistant to CTL-mediated apoptosis are not clear.
  • Using a human model of B-cell non-Hodgkin's lymphoma (B-cell NHL), we show that intratumoral T(reg) cells inhibit the proliferation and granule production of activated autologous infiltrating CD8(+) T cells.
  • Our results also show that degranulation and subsequent cytotoxic activity of infiltrating CD8(+) T cells exposed to lymphoma B cells is completely attenuated by the presence of intratumoral T(reg) cells.
  • Furthermore, we show that increased numbers of intratumoral T(reg) cells correlates with the number of CD8(+) T cells in biopsy specimens from patients with B-cell NHL, supporting the in vitro findings that intratumoral T(reg) cells inhibit proliferation of infiltrating CD8(+) T cells.
  • Taken together, these data indicate that human lymphoma B cells are sensitive to autologous CTL-mediated cell death but are protected by the inhibitory function of intratumoral T(reg) cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Dec;14(12):2149-58 [11187905.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):720-6 [11157023.001]
  • [Cites] J Immunol Methods. 2001 Jul 1;253(1-2):177-87 [11384679.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1070-7 [11493453.001]
  • [Cites] Blood. 2002 Jan 1;99(1):232-7 [11756176.001]
  • [Cites] Br J Haematol. 2002 Nov;119(2):425-31 [12406081.001]
  • [Cites] Nat Immunol. 2002 Dec;3(12):1208-13 [12415266.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1057-61 [12522256.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):330-6 [12612578.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):337-42 [12612581.001]
  • [Cites] Cancer Immunol Immunother. 2003 Jul;52(7):423-8 [12695859.001]
  • [Cites] J Immunol Methods. 2003 Oct 1;281(1-2):65-78 [14580882.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):310-7 [14722622.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1755-62 [14604957.001]
  • [Cites] Annu Rev Immunol. 2004;22:745-63 [15032595.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4251-8 [14976040.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] Immunity. 2004 Oct;21(4):589-601 [15485635.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1382-92 [7636203.001]
  • [Cites] Cancer Immunol Immunother. 1995 Sep;41(3):175-84 [7553687.001]
  • [Cites] Cell Immunol. 1996 Jul 10;171(1):10-9 [8660832.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1178-83 [9448305.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2875-85 [9531598.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3128-33 [10397255.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] J Immunol Methods. 2004 Nov;294(1-2):15-22 [15604012.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):419-24 [15623559.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2591-601 [15728465.001]
  • [Cites] J Exp Med. 2005 Mar 7;201(5):779-91 [15753211.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):263-74 [15776005.001]
  • [Cites] Hepatology. 2005 Apr;41(4):722-30 [15791620.001]
  • [Cites] Leukemia. 2005 May;19(5):835-40 [15744340.001]
  • [Cites] J Virol. 2005 Jun;79(12):7852-9 [15919939.001]
  • [Cites] J Virol. 2005 Jun;79(12):7860-7 [15919940.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jul;92(1):85-93 [15980996.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2018-25 [15914560.001]
  • [Cites] Blood. 2006 Jan 1;107(1):301-4 [16150935.001]
  • [Cites] Blood. 2006 Jan 15;107(2):628-36 [16179369.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2871-8 [16339406.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6659-64 [16617117.001]
  • [Cites] Blood. 2006 May 15;107(10):3940-9 [16410445.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6586-93 [16709816.001]
  • [Cites] Blood. 2006 May 1;107(9):3639-46 [16403912.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5211-8 [10553041.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3904-9 [11051236.001]
  • (PMID = 17047079.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA97274; United States / NCI NIH HHS / CA / R01 CA092104; United States / NCI NIH HHS / CA / CA92104; United States / NCI NIH HHS / CA / CA097274-060004; United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / R01 CA092104-05A2; United States / NCI NIH HHS / CA / P50 CA097274-060004; United States / NCI NIH HHS / CA / CA092104-05A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Membrane Glycoproteins; 0 / Pore Forming Cytotoxic Proteins; 126465-35-8 / Perforin; EC 3.4.21.- / GZMB protein, human; EC 3.4.21.- / Granzymes
  • [Other-IDs] NLM/ NIHMS89147; NLM/ PMC2680600
  •  go-up   go-down


3. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM: Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res; 2009 Jul 1;69(13):5522-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma.
  • Using biopsy specimens from patients with B-cell non-Hodgkin's lymphoma, we observed a significantly low frequency of T(H)17 cells, including several samples with no detectable amount of interleukin (IL)-17-producing cells present in the tumor microenvironment.
  • We found that, in the absence of lymphoma B cells, treatment with IL-1beta/IL-6 or lipopolysaccharide (LPS) enhanced IL-17 expression in CD4(+) T cells and this enhancement was attenuated when CD4(+) T cells were cocultured with lymphoma B cells.
  • Blockade of CD27-CD70 or CD28-CD80/86 interactions by anti-CD70 or anti-CD80/86 antibodies restored LPS-mediated induction of IL-17 expression in CD4(+) T cells cocultured with lymphoma B cells.
  • Because a subset of lymphoma B cells express IL-2 and given that IL-2 signaling is critically important in the development of regulatory T (T(reg)) cells, we tested the role of IL-2 signaling in T(H)17 cell development.
  • We found that treatment with anti-IL-2 antibody to interrupt IL-2 signaling significantly inhibited Foxp3 expression in CD4(+) T cells.
  • In contrast, interruption of IL-2 signaling up-regulated IL-17 expression in CD4(+) T cells and restored lymphoma-mediated down-regulation of IL-17-producing cells.
  • Furthermore, the reversal of T(reg) cell activity by LPS or CpG-A resulted in an enhancement of IL-17-producing cells.
  • Taken together, our study indicated that lymphoma B cells play an important role in skewing the balance between T(reg) and T(H)17 cells resulting in the establishment of a profoundly inhibitory tumor microenvironment.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Immunol. 2004 Dec;16(12):1769-80 [15520045.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Science. 2005 Aug 26;309(5739):1380-4 [16123302.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1133-41 [16200068.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1123-32 [16200070.001]
  • [Cites] Blood. 2006 May 1;107(9):3639-46 [16403912.001]
  • [Cites] Nature. 2006 May 11;441(7090):235-8 [16648838.001]
  • [Cites] Br J Haematol. 2006 Sep;134(6):596-601 [16889618.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10145-52 [17047079.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6B):4213-6 [17201135.001]
  • [Cites] Immunity. 2007 Mar;26(3):371-81 [17363300.001]
  • [Cites] Breast Cancer Res. 2007;9(1):R15 [17261184.001]
  • [Cites] J Immunol. 2007 Jun 1;178(11):6730-3 [17513719.001]
  • [Cites] Nat Immunol. 2007 Jun;8(6):639-46 [17486092.001]
  • [Cites] Science. 2007 Jul 13;317(5835):256-60 [17569825.001]
  • [Cites] Nature. 2007 Jul 26;448(7152):480-3 [17581589.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1849-61 [17635957.001]
  • [Cites] Nat Immunol. 2007 Sep;8(9):950-7 [17676044.001]
  • [Cites] Nat Immunol. 2007 Sep;8(9):942-9 [17676045.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2537-44 [17615291.001]
  • [Cites] Arthritis Rheum. 2007 Sep;56(9):2936-46 [17763419.001]
  • [Cites] Eur J Immunol. 2007 Nov;37(11):3155-63 [17918200.001]
  • [Cites] Front Biosci. 2008;13:1440-6 [17981641.001]
  • [Cites] Int Immunopharmacol. 2007 Dec 15;7(13):1819-24 [17996694.001]
  • [Cites] J Immunol. 2008 Jan 1;180(1):122-9 [18097011.001]
  • [Cites] J Immunol. 2008 Jan 1;180(1):214-21 [18097022.001]
  • [Cites] Clin Immunol. 2008 Apr;127(1):89-97 [18294918.001]
  • [Cites] Arthritis Rheum. 2008 Mar;58(3):875-87 [18311821.001]
  • [Cites] Gut. 2008 Jun;57(6):772-9 [17965063.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3915-23 [18483277.001]
  • [Cites] J Immunol. 2008 Jun 15;180(12):7948-57 [18523258.001]
  • [Cites] Blood. 2008 Jul 15;112(2):362-73 [18354038.001]
  • [Cites] J Exp Med. 2008 Aug 4;205(8):1903-16 [18663128.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2340-52 [18617638.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15505-10 [18832156.001]
  • [Cites] Nat Med. 2007 Jun;13(6):711-8 [17496900.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):720-6 [11157023.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Apr 6;282(3):735-8 [11401524.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:52-6 [12078904.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1033-6 [12532024.001]
  • [Cites] Prostate. 2003 Aug 1;56(3):171-82 [12772186.001]
  • [Cites] J Exp Med. 2003 Jul 21;198(2):235-47 [12874257.001]
  • [Cites] J Exp Med. 2003 Dec 15;198(12):1875-86 [14676299.001]
  • [Cites] J Cell Mol Med. 2003 Oct-Dec;7(4):472-4 [14754516.001]
  • [Cites] Annu Rev Immunol. 2004;22:531-62 [15032588.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5149-53 [15100250.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):113-20 [15305382.001]
  • [Cites] J Exp Med. 2005 Jan 3;201(1):127-37 [15630140.001]
  • (PMID = 19509224.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097274-070004; United States / NCI NIH HHS / CA / CA97274; United States / NCI NIH HHS / CA / R01 CA092104; United States / NCI NIH HHS / CA / CA092104-01A1; United States / NCI NIH HHS / CA / CA92104; United States / NCI NIH HHS / CA / CA097274-080004; United States / NCI NIH HHS / CA / CA097274-070004; United States / NCI NIH HHS / CA / R01 CA092104-01A1; United States / NCI NIH HHS / CA / P50 CA097274-080004; United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / R01 CA092104-05A2; United States / NCI NIH HHS / CA / CA092104-05A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Interleukin-17; 0 / Interleukin-2; 0 / Interleukin-23; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ NIHMS145634; NLM/ PMC2764404
  •  go-up   go-down


Advertisement
4. Arif A, Jamal S, Mushtaq S, Ahmed S, Mubarik A: Frequency of bcl-2 gene rearrangement in B-cell Non-Hodgkin's lymphoma. Asian Pac J Cancer Prev; 2009 Apr-Jun;10(2):237-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of bcl-2 gene rearrangement in B-cell Non-Hodgkin's lymphoma.
  • OBJECTIVE: The objective of the study was to determine the frequency of bcl-2 gene rearrangement in B-cell Non-Hodgkin's lymphoma (NHL) and identify different breakpoints of bcl-2 gene.
  • METHODS: Thirty cases of B-cell lymphoma (including 8 cases of follicular lymphoma, 19 cases of diffuse large B-cell lymphoma and 3 cases of T-cell rich B-cell lymphoma) were included in the study.
  • The polymerase chain reaction was done for major break point region (mbr), minor cluster region (mcr) and intermediate cluster region (icr) of the bcl-2 gene.
  • RESULTS: The bcl-2 gene rearrangement was identified in 23.3% of B-cell lymphoma, 50% of follicular lymphoma, 15% of diffuse large B-cell lymphoma and no bcl-2 rearrangement was identified in any of the T-cell rich B-cell lymphomas.
  • Further analysis showed the icr breakpoint in 16.7% of B-cell lymphoma, 37.5% of follicular lymphoma and 10.5% of diffuse large B-cell lymphoma.
  • Involvement of the mbr breakpoint was found in 6.7% of B-cell lymphoma, 12.5% of follicular lymphoma, and 5.3% of diffuse large B-cell lymphoma.
  • CONCLUSION: The bcl-2 gene rearrangement is quite frequent in follicular lymphoma, followed by diffuse large B-cell lymphoma.
  • This indicates that primers for bcl-2 gene must include icr primer, whenever the bcl-2 gene is being evaluated for B-cell NHL in this part of the world and this might reduce the variability of frequency of bcl-2 gene rearrangement within and between different regions.
  • [MeSH-major] Gene Rearrangement, B-Lymphocyte. Genes, bcl-2 / genetics. Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Female. Humans. Lymphoma, B-Cell / genetics. Lymphoma, Follicular / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Male. Middle Aged. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537891.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


5. Gouveris H, Hansen T, Franke K: Solitary extramedullary plasmacytoma and granulomatous sialadenitis of the parotid gland preceding a B-cell non-Hodgkin's lymphoma. Mund Kiefer Gesichtschir; 2006 Mar;10(2):122-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary extramedullary plasmacytoma and granulomatous sialadenitis of the parotid gland preceding a B-cell non-Hodgkin's lymphoma.
  • Ultrasonographically guided fine-needle biopsy could not provide any definitive diagnosis.
  • After partial parotidectomy with complete tumor removal the histologic exam showed an extramedullary plasmacytoma with concurrent non-necrotizing granulomatous sialadenitis of the parotid gland.
  • Complete systemic work-up excluded multiple myeloma, leukemia, lymphoma and sarcoidosis.
  • Six months after surgery an aggressive B-cell non-Hodgkin's lymphoma was diagnosed.
  • [MeSH-major] Granuloma / diagnosis. Lymphoma, B-Cell / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis. Parotid Neoplasms / diagnosis. Parotitis / diagnosis. Plasmacytoma / diagnosis
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Bone Marrow / pathology. CREST Syndrome / diagnosis. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Follow-Up Studies. Humans. Male. Parotid Gland / pathology. Parotid Gland / radiation effects. Parotid Gland / surgery. Postoperative Complications / diagnosis. Postoperative Complications / pathology. Prednisone / administration & dosage. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Sialadenitis.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1):111-6 [9894461.001]
  • [Cites] South Med J. 1998 May;91(5):493-5 [9598864.001]
  • [Cites] J Laryngol Otol. 1998 Feb;112(2):179-81 [9578882.001]
  • [Cites] J Clin Pathol. 1996 Mar;49(3):208-12 [8675730.001]
  • [Cites] Br J Dermatol. 2001 Jan;144(1):182-5 [11167703.001]
  • [Cites] Rheumatol Int. 1999;18(5-6):177-80 [10399792.001]
  • [Cites] Histopathology. 1987 Feb;11(2):131-44 [3570176.001]
  • [Cites] Arch Pathol Lab Med. 2002 Mar;126(3):365-8 [11860317.001]
  • [Cites] J Laryngol Otol. 1991 Aug;105(8):687-92 [1919333.001]
  • [Cites] Laryngol Rhinol Otol (Stuttg). 1986 Mar;65(3):127-9 [3713388.001]
  • [Cites] Laryngoscope. 1980 Mar;90(3):486-93 [7359969.001]
  • (PMID = 16489463.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


6. Dotan E, Aggarwal C, Smith MR: Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. P T; 2010 Mar;35(3):148-57
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.
  • Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy in adults, with B-cell lymphomas accounting for 85% of all NHLs.
  • The most substantial advancement in the treatment of B-cell malignancies, since the advent of combination chemotherapy, has been the addition of the monoclonal anti-CD20 antibody rituximab (Rituxan).
  • Since its initially reported single-agent activity in indolent lymphomas in 1997, the role of rituximab has expanded to cover both indolent and aggressive lymphomas.This article focuses on the impact of rituximab on the treatment, survival, and long-term outcomes of patients with indolent and aggressive lymphomas over the past two decades.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):389-97 [11208830.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1851-7 [10561225.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2257-9 [12200395.001]
  • [Cites] Radiologe. 2002 Dec;42(12):936-42 [12486547.001]
  • [Cites] Arthritis Rheum. 2003 Jun;48(6):1484-92 [12794814.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3051-9 [12837807.001]
  • [Cites] Exp Hematol. 2004 Jan;32(1):28-35 [14725898.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4416-23 [14976046.001]
  • [Cites] Ann Oncol. 2004 Mar;15(3):511-6 [14998858.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1454-9 [15024027.001]
  • [Cites] Curr Hematol Rep. 2004 Jul;3(4):227-9 [15217551.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]
  • [Cites] Curr Hematol Rep. 2004 Nov;3(6):395-6 [15496271.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1088-95 [15657401.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1103-8 [15657404.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5019-26 [15983392.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Ann Oncol. 1999 Dec;10(12):1419-32 [10643532.001]
  • [Cites] Nat Med. 2000 Apr;6(4):443-6 [10742152.001]
  • [Cites] Blood. 2000 May 15;95(10):3052-6 [10807768.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3900-8 [10845926.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3135-43 [10963642.001]
  • [Cites] Blood. 2001 Jan 1;97(1):101-6 [11133748.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):750-5 [11157027.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3295-301 [16873669.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4003-8 [16946304.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):364-9 [17079695.001]
  • [Cites] Onkologie. 2007 Mar;30(3):138-40 [17341901.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1986-92 [17420513.001]
  • [Cites] J Natl Cancer Inst. 2007 May 2;99(9):706-14 [17470738.001]
  • [Cites] Haematologica. 2007 Jun;92(6):826-33 [17550856.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Arch Intern Med. 2008 Mar 10;168(5):469-76 [18332290.001]
  • [Cites] Curr Oncol Rep. 2008 Jan;10(1):86-91 [18366965.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5486-95 [18390837.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3166-75 [18490650.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4473-9 [18626004.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4537-8 [18662966.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4579-86 [18662969.001]
  • [Cites] Blood. 2008 Dec 15;112(13):4824-31 [18799723.001]
  • [Cites] Cancer. 2008 Nov 15;113(10):2714-23 [18853418.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1607-14 [19255334.001]
  • [Cites] Blood. 2009 May 14;113(20):4834-40 [19264918.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):2983-90 [19414673.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8447-52 [16230674.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):242-9 [16397048.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1366-74 [7517442.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2457-66 [7522629.001]
  • [Cites] Immunol Today. 1994 Sep;15(9):450-4 [7524522.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] N Engl J Med. 1993 Dec 9;329(24):1770-6 [7694148.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1644-52 [9473230.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5137-44 [11431352.001]
  • (PMID = 20442809.001).
  • [ISSN] 1052-1372
  • [Journal-full-title] P & T : a peer-reviewed journal for formulary management
  • [ISO-abbreviation] P T
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2844047
  • [Keywords] NOTNLM ; non-Hodgkin’s lymphoma / rituximab
  •  go-up   go-down


7. Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y: Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy. Cancer Sci; 2009 Jan;100(1):54-61
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
  • It has been used to treat B-cell non-Hodgkin lymphoma (B-NHL), but recently rituximab resistance has been a cause for concern.
  • Pre-rituximab specimens comprised 34 follicular lymphomas (FL), 11 diffuse large B-cell lymphomas (DLBCL), 10 mantle cell lymphomas, two marginal zone B-cell lymphomas (MZBCL), and two chronic lymphocytic leukemias (CLL).
  • CD20 expression in lymphoma cells was evaluated by immunohistochemistry or flow cytometry.
  • Sixteen cases (27%) showed loss of CD20 expression with four histological patterns: pattern 1, no remarkable histological change (FL, 5; DLBCL, 3; and CLL, 2); pattern 2, proliferation of plasmacytoid cells (FL, 2; DLBCL, 1; and MZBCL, 1); pattern 3, transformation to classical Hodgkin's lymphoma (FL, 1); and pattern 4, transformation to anaplastic large cell lymphoma-like undifferentiated lymphoma (FL, 1).
  • Loss of CD20 was unrelated to the interval of biopsies, treatment regimen, clinical response, and frequency of rituximab administration.
  • In conclusion, B-NHL showed various histological and immunophenotypic changes after rituximab therapy, including not only CD20 loss but also proliferation of plasmacytoid cells or transformation to special subtypes of lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / analysis. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19038008.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


8. Ohno H: Pathogenetic and clinical implications of non-immunoglobulin ; BCL6 translocations in B-cell non-Hodgkin's lymphoma. J Clin Exp Hematop; 2006 Nov;46(2):43-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenetic and clinical implications of non-immunoglobulin ; BCL6 translocations in B-cell non-Hodgkin's lymphoma.
  • Chromosomal translocations affecting band 3q27, where BCL6 gene is located, are among the most common genetic abnormalities in non-Hodgkin's lymphoma of B-cell type (B-NHL).
  • The 3q27/BCL6 translocation is unique in that it can involve not only immunoglobulin (Ig) genes but also non-Ig chromosomal loci as a partner.
  • To date, around 20 non-Ig partner genes have been identified.
  • As a result of non-Ig ; BCL6 translocations, many types of regulatory sequences of each partner gene substitute for the 5' untranslated region of BCL6, and the rearranged BCL6 comes under the control of the replaced promoter.
  • The introduction of non-Ig ; BCL6 constructs into transformed cells led to high-level Bcl-6 protein expression in the nucleus, while BCL6 mRNA levels in clinical materials of diffuse large B-cell lymphoma (DLBCL) with non-Ig ; BCL6 translocations were unexpectedly low.
  • A comparative study suggested that non-Ig ; BCL6 translocation and a low level of BCL6 mRNA expression are concordant indicators of a poor clinical outcome in cases of DLBCL.
  • The coexistence of a non-Ig ; BCL6 translocation with t(14 ; 18)(q32 ;.
  • q21) in a single clone did not significantly affect the clinical features of follicular lymphoma.
  • The pathogenetic and clinical implications of non-Ig ; BCL6 translocations in B-NHL subtypes may not be identical to those of Ig ; BCL6.
  • [MeSH-major] DNA-Binding Proteins / genetics. Genetic Markers. Lymphoma, B-Cell / genetics. Translocation, Genetic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17142954.001).
  • [ISSN] 1346-4280
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Genetic Markers
  • [Number-of-references] 62
  •  go-up   go-down


9. Howe D, Bromidge T: Variation of LEF-1 mRNA expression in low-grade B-cell non-Hodgkin's lymphoma. Leuk Res; 2006 Jan;30(1):29-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation of LEF-1 mRNA expression in low-grade B-cell non-Hodgkin's lymphoma.
  • During normal B-lymphocyte development once cells pass the pro-B stage the transcription factor LEF-1, a key component of the Wnt/beta-catenin pathway, is down regulated.
  • However studies have shown that B-cell chronic lymphocytic leukaemia (CLL) lymphocytes, which have a mature B-cell phenotype, still express abundant LEF-1.
  • This study demonstrates that although LEF-1 mRNA is universally, highly expressed in B-CLL, expression of this gene is much lower or absent in the majority of low-grade B-cell non-Hodgkin's lymphoma (NHL).
  • This suggests that there exist key differences in the activity of the Wnt/beta-catenin pathway between low-grade B-cell malignancies.
  • [MeSH-major] Down-Regulation. Gene Expression Regulation, Leukemic. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lymphoid Enhancer-Binding Factor 1 / biosynthesis. Lymphoma, Non-Hodgkin / metabolism. Neoplasm Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16054689.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lymphoid Enhancer-Binding Factor 1; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


10. Meredith RF, Knox SJ: Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2006;66(2 Suppl):S15-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
  • Over the past several decades, several biomolecules have been investigated for their ability to deliver radiation to cancer cells, but antibodies have been the carriers of choice in systemic targeted radionuclide therapy (STaRT).
  • Food and Drug Administration for the treatment of patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), and clinical trials have shown that they are effective as monotherapies in the salvage setting, producing response rates that are often higher and durations of response that are often longer than those with chemotherapy.
  • Escalated doses of these agents can be supported with stem cell transplantation and can produce high rates of complete response and greater survival in patients with relapsed NHL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979433.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Iodine Radioisotopes; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 0 / iodine-131 anti-B1 antibody
  • [Number-of-references] 45
  •  go-up   go-down


11. Ogawa Y, Hotta T, Tobinai K, Watanabe T, Sasaki Y, Minami H, Morishima Y, Ogura M, Seriu T: Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma. Ann Oncol; 2006 Feb;17(2):330-3
Genetic Alliance. consumer health - Indolent B cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma.
  • BACKGROUND: The primary objective of this study was to investigate the tolerability, efficacy and pharmacokinetic profile of oral fludarabine phosphate in relapsed patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275653.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 106XV160TZ / Vidarabine Phosphate; 1X9VK9O1SC / fludarabine phosphate
  •  go-up   go-down


12. Wan SG, Sun XJ, Hui WH, He JJ, Liu CY, Zhao H, Sun WL, Su L, Xu J: [Multiparameter flow cytometric evaluation of bone marrow involvement in B cell non-Hodgkin's lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr;18(2):473-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiparameter flow cytometric evaluation of bone marrow involvement in B cell non-Hodgkin's lymphoma].
  • The objective of study was to evaluate the clinical values of multiparameter flow cytometry (MPFC) and cytomorphology of bone marrow aspiration(BMA) in detecting bone marrow involvement in patients with B cell Non-Hodgkin's lymphoma (B-NHL).
  • Bone marrow involvement in B-NHL detected by MPFC can be useful for clinical evaluation and prognosis prediction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20416192.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Emmanouilides C, Witzig TE, Gordon LI, Vo K, Wiseman GA, Flinn IW, Darif M, Schilder RJ, Molina A: Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Apr;47(4):629-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.
  • Yttrium 90 ((90)Y) ibritumomab tiuxetan (Zevalin), a radiolabeled monoclonal antibody against the CD20 antigen, is indicated for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma (NHL), including patients with rituximab-refractory follicular NHL.
  • Data on 211 patients treated in four clinical trials were analysed to compare the efficacy and safety of (90)Y ibritumomab tiuxetan when it was used after the first relapse of NHL and when it was used after two or more prior therapies.
  • Demographics, disease characteristics and the frequency of adverse events were similar in all groups, with the exception of a higher rate of marrow involvement in first-relapse patients than in patients with two or more prior therapies (57% vs. 39%; P < 0.05).
  • In patients with follicular NHL, the differences were even more pronounced (CR/CRu: 51% vs. 28%; P < 0.01; TTP: 15.4 vs. 9.2 months; P < 0.05). (90)Y ibritumomab tiuxetan has substantial clinical benefits as a second-line therapy, especially in patients with follicular NHL.
  • The quality of disease remissions obtained when (90)Y ibritumomab tiuxetan is administered after first relapse appears to be comparable with that observed with most chemotherapy regimens in first-relapse patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Radiopharmaceuticals / therapeutic use. Yttrium Radioisotopes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690521.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Radiopharmaceuticals; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


14. Tobinai K, Watanabe T, Ogura M, Morishima Y, Ogawa Y, Ishizawa K, Minami H, Utsunomiya A, Taniwaki M, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Hayashi M, Seriu T, Hotta T: Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma. J Clin Oncol; 2006 Jan 1;24(1):174-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma.
  • PURPOSE: Although intravenous (IV) fludarabine phosphate is effective against indolent B-cell non-Hodgkin's lymphoma (B-NHL), IV administration for 3 to 5 consecutive days is inconvenient in an outpatient setting.
  • The efficacy was separately analyzed in a mantle-cell lymphoma (MCL) cohort and indolent B-NHL except for MCL (IL) cohort.
  • RESULTS: Fifty-two patients, including 46 in the IL cohort (41 with follicular lymphoma) and six in the MCL cohort, were registered, and all patients were eligible.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Lymphoma, B-Cell / drug therapy. Vidarabine Phosphate / analogs & derivatives

  • Genetic Alliance. consumer health - Indolent B cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330664.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 106XV160TZ / Vidarabine Phosphate; 1X9VK9O1SC / fludarabine phosphate
  •  go-up   go-down


15. Dong M, Ning Z, Newman MJ, Xu J, Dou G, Cao H, Shi Y, Gingras MA, Lu X, Feng F: Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. J Clin Oncol; 2009 May 20;27(15_suppl):3529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.
  • : 3529 Background: Chidamide (CS055/HBI-8000) is a new benzamide type of histone deacetylase (HDAC) inhibitor with low nanomolar activity against HDAC1, 2, 3 and 10.
  • This Phase I study evaluated the safety and tolerability of chidamide in patients (pts) with advanced solid tumors and lymphomas.
  • METHODS: 31 pts with refractory or relapsed advanced solid tumors (22) and lymphomas (9) were enrolled in this study.
  • Significant induction of histone (H3) acetylation was observed in peripheral white blood cells, which lasted for 2-3 days in most pts after single dosing.
  • 4 pts with T-cell lymphomas (4/5 evaluable) and 1 pt with submandibular adenoid cystic carcinoma achieved PR, and 11 pts (2 B-cell lymphomas and 9 solid tumors) experienced SD.
  • CONCLUSIONS: Chidamide was well-tolerated in pts with advanced solid tumors and lymphomas in the tested regimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961317.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Saleh MN, Pitot H, Maleski J, Leopold L, Forero A: Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e14537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers.
  • : e14537 Background: Over-expression of Bcl-2 family proteins is common in human cancers.
  • Initial trials of the oral, pan-Bcl-2 inhibitor AT-101 showed acute dose limiting toxicity of Gr 3-4 AST/ALT (MTD 40 mg/d) and ileus with prolonged dosing daily (QD) for 21/28 days per cycle (Saleh, NCI/EORTC, 2005; James, ASCO, 2006 and Saleh, ASCO, 2007).
  • Stable disease was reported in 13/37 (35%) pts.
  • One pt with NSCLC continues on study with stable disease for 33 cycles and 2 additional pts were on study with stable disease for 18 and 9 cycles.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963553.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Ferrucci PF, Vanazzi A, Tesoriere G, Ferrari M, Bartolomei M, Rocca P, Cremonesi M, Paganelli G, Martinelli G: Cerebrospinal fluid diffusion of Zevalin after high-activity treatment and stem cell support in a patient affected by diffuse large B-cell non-Hodgkin's lymphoma with central nervous system involvement. Ann Oncol; 2005 Oct;16(10):1710-1
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebrospinal fluid diffusion of Zevalin after high-activity treatment and stem cell support in a patient affected by diffuse large B-cell non-Hodgkin's lymphoma with central nervous system involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15972281.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / ibritumomab tiuxetan
  •  go-up   go-down


18. Visani G, Isidori A: Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand. Expert Rev Anticancer Ther; 2009 Mar;9(3):357-63
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand.
  • Anthracyclines, including doxorubicin, are widely used in the treatment of B-cell non-Hodgkin's lymphoma (NHL).
  • However, their clinical potential is limited by their cardiotoxic adverse effects, which include cardiomyopathy and congestive heart failure.
  • Nonpegylated liposomal doxorubicin produced a promising response rate when substituted for conventional doxorubicin in the cyclophosphamide, doxorubicin, vincristine and prednisolone regimen in the treatment of patients with NHL either at diagnosis or at relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / administration & dosage. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Humans. Liposomes. Lymphoma, AIDS-Related / drug therapy. Middle Aged. Prednisolone / administration & dosage. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19275512.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Liposomes; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  • [Number-of-references] 31
  •  go-up   go-down


19. Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T, Berthold F, Janka-Schaub G, Klein C, Kabickova E, Klapper W, Attarbaschi A, Schrappe M, Reiter A, Berlin-Frankfurt-Münster group: Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol; 2010 Jul 1;28(19):3115-21
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.
  • PURPOSE: The activity of rituximab in pediatric B-cell non-Hodgkin's lymphoma (B-NHL) has not yet been determined.
  • Responders had > or = 25% decrease of at least one lesion or BM or PB blasts and no disease progress at other sites.
  • Of 87 evaluable patients, 36 were responders (RR, 41.4%; 95% CI, 31% to 52%); among them, 27 of 67 with Burkitt lymphoma and seven of 15 with diffuse large B-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Jul 1;28(19):3104-6 [20516430.001]
  • (PMID = 20516455.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


20. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2005 Feb 1;23(4):667-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
  • PURPOSE: Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
  • PATIENTS AND METHODS: Patients were stratified, based on preclinical data, into arm A (mantle-cell lymphoma) or arm B (other B-cell lymphomas) without limitation in number of prior therapies.
  • RESULTS: Sixty patients with a median number of prior therapies of 3.5 (range, one to 12 therapies) were enrolled; 33 patients were in arm A and 27 were in arm B, including 12 diffuse large B-cell lymphomas, five follicular lymphomas (FL), three transformed FLs, four small lymphocytic lymphomas (SLL), two Waldenstrom's macroglobulinemias (WM), and one marginal zone lymphoma.
  • In arm B, four of 21 assessable patients responded (one SLL patient had a CR, one FL patient had a CR unconfirmed, one diffuse large B-cell lymphoma patient had a PR, and one WM patient had a PR) for an ORR of 19% (95% CI, 5% to 42%).
  • Grade 4 toxicity occurred in nine patients (15%), and three deaths from progression of disease occurred within 30 days of withdrawal from study.
  • CONCLUSION: Bortezomib showed promising activity in relapsed mantle-cell lymphoma and encouraging results in other B-cell lymphomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Lymphoma, B-Cell / drug therapy. Protease Inhibitors / therapeutic use. Pyrazines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Feb 1;23(4):657-8 [15613690.001]
  • (PMID = 15613697.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


21. Micallef IN, Maurer MJ, Nikcevich DA, Cannon MW, Schaefer EW, Moore DF, Kurtin P, Witzig TE: Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma.
  • : 8508 Background: A prior pilot study of epratuzumab (Immunomedics) and rituximab in combination with CHOP chemotherapy (ER-CHOP) in untreated patients with diffuse large B-cell lymphoma demonstrated feasibility and safety.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960859.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Li B, Zhong MZ, Tang TF, Liu W, Huang J: [Correlation of cyclooxygenase-2 expression to P-glycoprotein expression in B-cell non-Hodgkin's lymphoma]. Ai Zheng; 2007 Aug;26(8):851-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of cyclooxygenase-2 expression to P-glycoprotein expression in B-cell non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: The overexpression of P-glycoprotein (P-gp) plays an important role in the chemoresistance of relapsed lymphoma.
  • This study was to observe the expression and correlation of COX-2 and P-gp in B-cell non-Hodgkin's lymphoma (B-NHL), and to investigate their correlations to clinicopathologic features of B-NHL.
  • [MeSH-major] Cyclooxygenase 2 / metabolism. Lymphoma, B-Cell / metabolism. P-Glycoprotein / metabolism
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697546.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / P-Glycoprotein; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


23. Wiseman GA, Witzig TE: Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm; 2005 Apr;20(2):185-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
  • AIM: Yttrium-90 ((90)Y) ibritumomab tiuxetan (Zevalin) radioimmunotherapy is an effective treatment for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), with overall response rates ranging from 74% to 82%.
  • MATERIALS AND METHODS: The medical records of patients (n = 211) with relapsed, refractory, or transformed indolent CD20+ B-cell NHL who were treated with 90Y ibritumomab tiuxetan were reviewed.
  • CONCLUSIONS: (90)Y ibritumomab tiuxetan produces durable long-term responses in patients with relapsed/refractory B-cell NHL.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Lymphoma, B-Cell / pathology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / radiotherapy. Yttrium Radioisotopes / pharmacology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD20 / biosynthesis. Disease Progression. Female. Humans. Male. Middle Aged. Radioimmunotherapy / methods. Recurrence. Retrospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15869453.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


24. Morales D, Beltran B, Hurtado de Mendoza F, Riva L, Quiñones P: Analysis of prognostic factors in patients with EBV positive diffuse large B cell lymphoma of the elderly. J Clin Oncol; 2009 May 20;27(15_suppl):e19542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors in patients with EBV positive diffuse large B cell lymphoma of the elderly.
  • : e19542 Background: EBV positive diffuse large B cell lymphoma of the elderly is a new entity included in the Fourth edition of WHO Classification.
  • AIM: The goal of this study was to evaluate clinical characteristics and survival of EBV positive diffuse large B cell lymphoma of the elderly from Peruvian patients.
  • METHODS: Between January 2002 and June 2008, eleven patients with EBV positive diffuse large B cell lymphoma of the elderly were included in the analysis.
  • All cases were positive to the presence of EBV encoded RNA (EBER) by CISH and CD20 and/or Pax-5 expression by immunohistochemistry.Clinical data were reviewed retrospectively and patient's biopsies were analyzed for the immunohistochemical expression of BCL6, CD10, CD30 and MUM-1/IRF4 by tissue microarray (TMA) technique..
  • Extranodal disease occurred in 6/11 (54%) patients: pleura (n=2), suprarenal gland (n=1), stomach (n=1), cecum (n=1), bone (1), skin (1) and bone marrow (n=1).
  • Ten cases (83%) were of the Non-GC and 1 case was GC.
  • Complete response (n=2), partial response (n=0) and progressive disease (n=3).
  • CONCLUSIONS: EBV positive diffuse large B cell lymphoma of the elderly was related to high IPI, poor ECOG, frequent extranodal disease, poor response to treatment and very short survival.
  • It is the first report of this entity in a non-Asian population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960995.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Roberts AW, Wilson W, Gandhi L, O'Connor OA, Rudin CM, Brown JR, Xiong H, Chiu Y, Enschede S, Krivoshik AP: Ongoing phase I studies of ABT-263: Mitigating Bcl-X&lt;sub&gt;L&lt;/sub&gt; induced thrombocytopenia with lead-in and continuous dosing. J Clin Oncol; 2009 May 20;27(15_suppl):3505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ongoing phase I studies of ABT-263: Mitigating Bcl-X<sub>L</sub> induced thrombocytopenia with lead-in and continuous dosing.
  • : 3505 Background: ABT-263, a novel, oral BH3 mimetic, potently inhibits multiple antiapoptotic Bcl-2 family proteins.
  • Ongoing phase 1 studies of ABT-263 show anti-tumor activity in CLL and some lymphomas (Wilson W et al, ASH. 2008).
  • However, thrombocytopenia (TCP) due to on-target Bcl-X<sub>L</sub> inhibition-induced platelet apoptosis is also observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961281.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Maraj I, Hernandez-Ilizaliturri FJ, Chisti M, Czuczman MS: Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib. J Clin Oncol; 2009 May 20;27(15_suppl):8576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib.
  • : 8576 Deacetylases (DACs) are enzymes that remove the acetyl groups from target proteins [histones (class I) and non-histones (class II)], leading to regulation of gene transcription and other cellular processes.
  • LBH589 is a novel and potent DAC class I and II Inhibitor undergoing pre-clinical and clinical testing.
  • In order to develop therapeutic options for refractory/resistant B-cell lymphomas we studied the effects of LBH589 in the anti-tumor activity of chemotherapy agents and monoclonal antibodies in a panel of rituximab-sensitive cell lines (RSCL), rituximab-resistant cell lines (RRCL), and in lymphoma cells isolated from patients with treatment-naïve or refractory/relapsed B-cell lymphomas by negative selection using magnetic beads.
  • NHL cells lines were exposed to the following chemotherapy agents or monoclonal antibodies: CDDP, doxorubicin, vincristine, bortezomib or rituximab, veltuzumab, or isotype, alone or in combination with LBH589.
  • Patient-derived tumor cells were exposed to either LBH589, bortezomib or both.
  • Changes in ATP content were determined by cell titer glow assay.
  • RNA was isolated from NHL cell lines exposed to LBH859 and changes in gene expression of the Bcl-2 family members were determined by qualitative polymerase chain reaction (PCR).
  • LBH589 was active as a single agent against RSCL, RRCL or patient-derived tumor cells.
  • In addition, Bcl-XL gene down-regulation was observed following exposure to LBH859.
  • Our data suggests that LBH589 is active against various RSCL, RRCL and patient-derived tumor cells.
  • Findings suggest that LBH589 added to systemic anti-CD20 and/or chemotherapy could result in a novel and potent treatment strategy against B-cell lymphomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962275.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Wang M, Zhou Y, Zhang L, Nguyen CA, Romaguera J: Use of bortezomib in B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther; 2006 Jul;6(7):983-91
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of bortezomib in B-cell non-Hodgkin's lymphoma.
  • The ubiquitin-proteasome pathway plays a critical role in the regulated degradation of proteins involved in cell cycle control and tumor growth.
  • In preclinical studies, bortezomib has demonstrated activity against a variety of B-cell malignancies by inducing apoptosis and sensitizing tumor cells to radiation or chemotherapy.
  • Based on these findings, clinical trials have been conducted with bortezomib in B-cell non-Hodgkin's lymphoma.
  • In these studies, bortezomib was generally well tolerated with manageable toxicities and showed promising clinical activity.
  • Mantle cell lymphoma was significantly more sensitive to bortezomib than other non-Hodgkin's lymphomas.
  • Bortezomib may have far-reaching potential in the treatment of B-cell non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Bortezomib. Clinical Trials as Topic. Humans. Lymphoma, Follicular / drug therapy. Multiple Myeloma / drug therapy. Waldenstrom Macroglobulinemia / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831071.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  • [Number-of-references] 51
  •  go-up   go-down


28. Zareifar S, Geramizadeh B, Sharifian M: Simultaneous manifestation of fulminant infectious mononucleosis with B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2007 Jul 1;25(19):2851-2
MedlinePlus Health Information. consumer health - Infectious Mononucleosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous manifestation of fulminant infectious mononucleosis with B-cell non-Hodgkin's lymphoma.
  • [MeSH-major] Hodgkin Disease / complications. Hodgkin Disease / diagnosis. Infectious Mononucleosis / complications. Infectious Mononucleosis / diagnosis. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Cell Proliferation. Child. Fatal Outcome. Humans. Immunohistochemistry. Lymph Nodes / virology. Male

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17602091.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Soufla G, Baritaki S, Sifakis S, Zafiropulos A, Spandidos DA: Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with malignant transformation of the uterine cervix. Int J Biol Markers; 2005 Jan - Mar;20(1):18-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with malignant transformation of the uterine cervix.
  • : Deregulation of the apoptotic machinery plays a major role in cell death, cellular transformation and cancer. p53, Bcl-2, Bcl-XL, Bax and Mdm2 mRNA expression patterns were evaluated in tissue samples with cervical intraepithelial neoplasia (CIN) and cervical cancer compared to those of normal cervical tissues, and correlated with the underlying cervical lesions.
  • Transcript levels of the above genes were assessed by RT-PCR analysis in a total of 44 cervical specimens. p53, Bcl-2, Bax and Mdm2 transcript levels were significantly different in the normal, CIN and cancer specimen groups (p=0.003, p=0.009, p=0.040 and p=0.001, respectively).
  • Specifically, p53, Bax and Bcl-2 exhibited substantially lower transcript levels in CIN lesions compared to controls, whereas Bax mRNA levels showed a significant decrease in cancer compared to normal specimens.
  • High-grade squamous intraepithelial lesions exhibited lower p53 and Bcl-2 mRNA levels than controls (p=0.002, p=0.016).
  • Coexpression analysis revealed more correlations between the above apoptosis-related molecules in normal tissues compared to CIN or cancer specimens. p53 showed significant coexpression with Bax, Bcl-2 and Mdm2 (p=0.040, p=0.013 and p=0.015, respectively) in normal cervical specimens.
  • Bax and Bcl-XL mRNA expression was negatively correlated.
  • Mdm2 transcriptional levels correlated significantly with those of Bax, Bcl-XL and Bcl-2.
  • Our findings show that p53, Bax, Bcl-2 and Mdm2 mRNA expression levels correlate with the malignant transformation of the uterine cervix. mRNA coexpression patterns of the members of the pro- and anti-apoptotic family examined in cervical carcinogenesis were found to be disrupted in CIN and cancer, as already demonstrated at the protein level. (Int J Biol Markers 2005; 20: 18-27).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207100.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


30. Fiveash JB, Chowdhary SA, Peereboom D Jr, Mikkelsen T, Nabors LB, Lesser GJ, Rosenfeld MR, Ye X, Grossman SA: NABTT-0702: A phase II study of R-(-)-gossypol (AT-101) in recurrent glioblastoma multiforme (GBM). J Clin Oncol; 2009 May 20;27(15_suppl):2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2010 Background: R-(-)-gossypol (AT-101) is an oral bcl-2 family protein inhibitor (Bcl-2, Bcl-X<sub>L</sub>, Mcl-1, Bcl-W) and potent inducer of proapoptotic proteins.
  • A prior study of racemic gossypol demonstrated objective responses in patients with malignant glioma.
  • METHODS: Fifty-six patients with recurrent GBM were enrolled in this multi-institution phase II clinical trial through the NABTT CNS consortium designed to detect a 33% increase in overall survival (OS, primary endpoint) from 5 to 6.65 months with Power/Alpha 80%/0.01.
  • Seven patients (16%) had stable disease as the best response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964593.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Pitot HC, Mould D, Maleski J, Leopold L: Analysis of a phase I pharmacokinetic (PK)/food effect study of AT-101 in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2557

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2557 Background: AT-101 is an oral, pan-Bcl-2 inhibitor (Bcl-2, Bcl-XL, Bcl-W, Mcl-1).
  • Overexpression of Bcl-2 family proteins is common in human cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961871.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Sen A, Mukherjee B: Primary B-cell non-Hodgkin's lymphoma the commonest testicular malignancy of the elderly. Indian J Pathol Microbiol; 2007 Jul;50(3):600-1
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary B-cell non-Hodgkin's lymphoma the commonest testicular malignancy of the elderly.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Non-Hodgkin / pathology. Testicular Neoplasms / pathology. Testis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883152.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  •  go-up   go-down


33. Cheson BD, Leonard JP: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med; 2008 Aug 7;359(6):613-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / immunology. Antigens, Surface. B-Lymphocytes / immunology. Drug Resistance, Neoplasm. Humans. Immunotherapy. Rituximab

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] N Engl J Med. 2009 Jan 8;360(2):192-3; author reply 193 [19137630.001]
  • [CommentIn] N Engl J Med. 2009 Jan 8;360(2):192; author reply 193 [19129537.001]
  • (PMID = 18687642.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antigens, Surface; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 114
  •  go-up   go-down


34. Manckoundia P, Martin-Pfitzenmeyer I, Pfitzenmeyer P: Myasthenia gravis associated with a B-cell, non-Hodgkin's lymphoma. Eur J Intern Med; 2006 Mar;17(2):146

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myasthenia gravis associated with a B-cell, non-Hodgkin's lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16490698.001).
  • [ISSN] 0953-6205
  • [Journal-full-title] European journal of internal medicine
  • [ISO-abbreviation] Eur. J. Intern. Med.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


35. Bienert M, Reisinger I, Srock S, Humplik BI, Reim C, Kroessin T, Avril N, Pezzutto A, Munz DL: Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience. Eur J Nucl Med Mol Imaging; 2005 Oct;32(10):1225-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.
  • PURPOSE: The aim of this study was to evaluate the safety, toxicity and therapeutic response of non-myeloablative radioimmunotherapy using 131I-rituximab in previously heavily treated patients with B-cell non-Hodgkin's lymphoma (B-NHL).
  • Four patients had received prior high-dose chemotherapy followed by autologous stem cell transplantation, and eight had received prior rituximab therapy.
  • Histopathology consisted of four mantle cell, one follicular and four diffuse large B-cell lymphomas.
  • Four non-responders with bulky disease died 4.8+/-2.0 months after therapy.
  • Of two patients who received radioimmunotherapy as an additional treatment after salvage chemotherapy, one continues to be disease-free at 9 months and one relapsed at 5 months' follow-up.
  • Radioimmunotherapy was less efficient in patients with bulky disease and elevated LDH.
  • Severe haematological toxicity in seven patients did not cause significant clinical problems.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Neoplasm Recurrence, Local / prevention & control. Radioimmunotherapy / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1263-70 [12663713.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Cancer Pract. 1998 May-Jun;6(3):195-7 [9652253.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1587-94 [9193357.001]
  • [Cites] Cancer. 2002 Feb 15;94(4 Suppl):1363-72 [11877767.001]
  • [Cites] Clin Immunol. 2001 Jul;100(1):40-8 [11414744.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):58-65 [10561019.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10 ):2453-63 [12011122.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1259-66 [10942366.001]
  • [Cites] Nuklearmedizin. 2002 Apr;41(2):71-9 [11989301.001]
  • [Cites] Lancet. 1995 Aug 5;346(8971):336-40 [7623531.001]
  • [Cites] J Nucl Med. 1990 Jan;31(1):84-9 [2295945.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1023-30 [8450856.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3281s-3286s [10541376.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Oct;29(10 ):1276-82 [12271407.001]
  • [Cites] J Clin Oncol. 1996 Jul;14 (7):1974-81 [8683227.001]
  • [Cites] J Nucl Med. 1998 Aug;39(8 Suppl):21S-27S [9708567.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3246-56 [9779698.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3793-803 [10577851.001]
  • [Cites] Lancet Oncol. 2004 Jun;5(6):341-53 [15172354.001]
  • [Cites] Cancer Biother Radiopharm. 2003 Aug;18(4):513-24 [14503945.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3304s-3314s [10541379.001]
  • [Cites] N Engl J Med. 1993 Oct 21;329(17):1219-24 [7692295.001]
  • [Cites] Cancer Immunol Immunother. 2003 May;52(5):281-96 [12700944.001]
  • [Cites] J Clin Oncol. 1986 Oct;4(10):1470-80 [3531422.001]
  • [Cites] Eur J Nucl Med. 2000 Jul;27(7):766-77 [10952488.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10 ):3270-8 [9779701.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1027-38 [2666588.001]
  • [Cites] Eur J Haematol. 2004 Jan;72(1):10-7 [14962257.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] J Clin Oncol. 1992 Nov;10 (11):1696-711 [1403053.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • (PMID = 15937686.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 131I-rituximab; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Radiopharmaceuticals
  •  go-up   go-down


36. Larouche J, Berger F, Chassagne-Clement C, Sebban C, Ghesquieres H, Salles G, Coiffier B: Lymphoma recurrence 5 years or more following diffuse large B-cell lymphoma: Clinical characteristics and outcome. J Clin Oncol; 2009 May 20;27(15_suppl):8562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma recurrence 5 years or more following diffuse large B-cell lymphoma: Clinical characteristics and outcome.
  • : 8562 Background: Diffuse large B-cell lymphoma (DLBCL) usually relapses early following treatment but some relapses happen 5 years or later.
  • Few data exist regarding clinical characteristics and outcome of these patients (pts).
  • METHODS: We performed a retrospective analysis of all pts from two centers in Lyon/France between 1980-2003 who presented a biopsy proven relapse 5 years or later following diagnosis of DLBCL.
  • Clinical characteristics at diagnosis were: median age 57 y; stage I-II 63% (34/54); IPI low/low intermediate 84% (41/49) and extranodal involvement (EN) 66% (35/53).
  • IHC at diagnosis: CD20 100% (46/46), CD10 28% (10/36), bcl-6 53% (9/17), MUM1 48% (11/23), bcl-2 68% (19/28), germinal-center phenotype (GC) 57% (12/21) and non-GC 43% (9/21).
  • Median time from diagnosis to relapse was 7.4 years (5-20.5 years).
  • MUM1 expression at diagnosis was associated with DLBCL histology at relapse (p=0.037).
  • Clinical characteristics at relapse were: median age 66 y; stage I-II 48% (26/54); 73% (31/43) with DLBCL at relapse had EN.
  • 54% (15/28) with DLBCL at relapse had a GC phenotype and 46% (13/28) a non-GC phenotype.
  • CONCLUSIONS: Patients with DLBCL who present a late relapse usually had localized stage, favorable IPI and extranodal involvement at diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960984.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Yan JS, Chen XY, Li WP, Yang Y, Song ZL: Establishing SCID mouse models of B-cell non-Hodgkin's lymphoma. Ai Zheng; 2009 Feb;28(2):181-3
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishing SCID mouse models of B-cell non-Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVE: Recently, the incidence of non-Hodgkin's lymphoma (NHL) is increasing, in which most are aggressive.
  • In this study, mouse models of B-cell NHL were established for determining the efficacy and mechanisms of novel therapies.
  • METHODS: Diffuse large B-cell lymphoma SU-DHL-4 cells and Burkitt's lymphoma Daudi cells were injected into SCID (severe combined immunodeficiency) mice through the tail veins to observe the presentations and requirements for establishing mouse models.
  • The Daudi-cell lymphoma mice were divided into control group and rituximab group, and the latter received treatment of rituximab.
  • RESULTS: The median onset time of SU-DHL-4-cell lymphoma in SCID mice was 39.5 days, which presented cachexia, weight loss, erect hair, tardiness and enlarged tumors in the abdomen, rump or pelvic limb, but without tumor cell infiltration in the liver, spleen or bone marrow.
  • The median onset time of Daudi-cell lymphoma in SCID mice was 30.5 days, which were characterized by paralyzed lower limbs and died about 9.5 days after paralysation.
  • Most organs such as the liver, kidney, spleen and bone marrow were infiltrated by a number of Daudi cells.
  • After treatment of rituximab, Daudi cells presented typical characteristics of apoptosis.
  • The median paralysis time and survival time of mice with Daudi-cell lymphoma were significantly longer in rituximab group than in control group (52.5 days vs. 30.5 days, 76.5 days vs. 40 days, p < 0.05).
  • CONCLUSION: SCID mouse models of B-cell lymphoma can be successfully established with either SU-DHL-4 cells or Daudi cells.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Xenograft Model Antitumor Assays / methods
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / immunology. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Female. Humans. Mice. Mice, SCID. Rituximab. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19550134.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


38. Shah J, Wang W, Harrough VD, Saville W, Meredith R, Shen S, Mueh J, Lister J, Jasthy S, Maggass G, McKay C, Krumdieck R, Tharp M, Winter C, Gregory S, Buchholz W, Awasthi S, Jacobs S, Chung H, Egner J, Lobuglio AF, Forero A: Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma. Leuk Lymphoma; 2007 Sep;48(9):1736-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.
  • In this work, data on patients with B-cell NHL who were treated with two courses of ibritumomab tiuxetan were analyzed.
  • Eighteen such patients were analyzed (age: 58 years, 48 - 91), with a median of four prior regimens (1 - 7), stem cell transplantation (n = 5), and radiation therapy (n = 6).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy. Yttrium Radioisotopes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786709.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


39. Kassam S, Montoto S: Oncologic, endocrine & metabolic emerging drugs in B-cell non-Hodgkin's lymphoma. Expert Opin Emerg Drugs; 2008 Jun;13(2):323-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncologic, endocrine & metabolic emerging drugs in B-cell non-Hodgkin's lymphoma.
  • BACKGROUND: The incidence of non-Hodgkin's lymphoma, of which B-cell neoplasms are the commonest, has been increasing over the last 20 years.
  • However, treatment failure with disease recurrence remains a major problem.
  • OBJECTIVES: To review preclinical and clinical data on novel molecularly targeted therapies that show promise for the treatment of B-cell NHL.
  • RESULTS/CONCLUSION: Large numbers of new drugs are at various stages of preclinical and clinical development.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Delivery Systems. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Drug Design. Female. Humans. Immunotherapy. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / physiopathology. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / physiopathology. Male. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537524.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 149
  •  go-up   go-down


40. Fischer M, Grünwald F, Knapp WH, Trümper L, von Schilling C, Dreyling M, Deutsche Gesellschaft für Nuklearmedizin, Deutsch Gesellschaft für Hämatologie und Onkologie: [Guideline for radioimmunotherapy of CD20+ follicular B-cell non-Hodgkin's lymphoma]. Nuklearmedizin; 2009;48(6):215-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Guideline for radioimmunotherapy of CD20+ follicular B-cell non-Hodgkin's lymphoma].
  • [Transliterated title] Leitlinie für die Radioimmuntherapie des CD20-positiven follikulären B-Zell-Non-Hodgkin-Lymphoms.
  • This guideline is a prerequisite for the quality management in the treatment of non-Hodgkon-lymphomas in patients with relapsed or refractory follicular lymphoma after rituximab therapy and as consolidation therapy after first remission following CHOP like treatment using radioimmunotherapy.
  • For instance, presence of an expert for medical physics, intense cooperation with all colleagues committed to treatment of lymphomas, and a certificate of instruction in radiochemical labelling and quality control are required.
  • After treatment, clinical quality control is mandatory (work-up of therapy data and follow-up of patients).
  • The complete treatment inclusive after-care has to be realised in close cooperation with those colleagues (hemato-oncologists) who propose, in general, radioimmunotherapy under consideration of the development of the disease.
  • [MeSH-major] Antigens, CD2 / immunology. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / radiotherapy. Nuclear Medicine / standards. Quality Assurance, Health Care / standards. Radiation Oncology / standards. Radioimmunotherapy / standards

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19902120.001).
  • [ISSN] 0029-5566
  • [Journal-full-title] Nuklearmedizin. Nuclear medicine
  • [ISO-abbreviation] Nuklearmedizin
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Practice Guideline
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD2
  •  go-up   go-down


41. Carbone J, Perez-Fernandez R, Muñoz A, Sabin P, Carreño L, Fernandez-Cruz E: Combined therapy with rituximab plus cyclophosphamide/vincristine/prednisone for Sjogren's syndrome-associated B-cell non-Hodgkin's lymphoma. Clin Rev Allergy Immunol; 2008 Feb;34(1):80-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined therapy with rituximab plus cyclophosphamide/vincristine/prednisone for Sjogren's syndrome-associated B-cell non-Hodgkin's lymphoma.
  • Sjogren's syndrome (SS) is characterized by an increased risk of developing non-Hodgkin's lymphoma (NHL).
  • NHL, which expresses the CD20 antigen on tumor cell surfaces, is a disease entity candidate to treatment with anti-CD20 monoclonal antibodies.
  • We report clinical and immunological data of a patient with SS and NHL who was treated with a regimen consisting of cyclophosphamide/vincristine/prednisone (CVP) plus rituximab.
  • The clinical course of SS was complicated with severe splenomegaly.
  • An increased percentage of CD19+ B cells (up to 30%) was detected in peripheral blood during follow-up.
  • Low-grade B marginal zone lymphoma was diagnosed (peripheral blood immunophenotype: CD19+CD20+CD23+sIg+Kappa; bone marrow immunophenotype: 25% lymphocytes; CD19+CD20+CD79A/BCL2+).
  • [MeSH-major] Antibodies, Monoclonal. Antineoplastic Agents. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Sjogren's Syndrome / complications

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rheumatology (Oxford). 2004 Aug;43(8):1050-3 [15187246.001]
  • [Cites] Eur J Haematol Suppl. 2007 Jan;(67):5-14 [17206982.001]
  • [Cites] Curr Opin Immunol. 2002 Aug;14(4):517-21 [12088688.001]
  • [Cites] Ann Rheum Dis. 2007 Mar;66(3):351-7 [16950808.001]
  • [Cites] Am J Hematol. 1991 Jun;37(2):69-74 [1829873.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] Ann Rheum Dis. 2002 Jun;61(6):554-8 [12006334.001]
  • [Cites] Ann Rheum Dis. 2005 Jun;64(6):958-60 [15576414.001]
  • [Cites] Arthritis Rheum. 1999 Aug;42(8):1765-72 [10446879.001]
  • [Cites] Lupus. 2004;13(12):969-71 [15645755.001]
  • [Cites] Clin Immunol Immunopathol. 1994 Jan;70(1):60-5 [8261670.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] Arthritis Rheum. 2005 Sep;52(9):2740-50 [16142737.001]
  • [Cites] Arthritis Rheum. 2003 Jun 15;49(3):394-8 [12794796.001]
  • [Cites] Clin Exp Rheumatol. 2006 Jul-Aug;24(4):438-48 [16956437.001]
  • [Cites] Clin Exp Immunol. 2003 Nov;134(2):314-20 [14616793.001]
  • [Cites] Arthritis Rheum. 2004 Nov;50(11):3580-90 [15529346.001]
  • [Cites] J Immunol. 2007 Feb 15;178(4):2287-95 [17277134.001]
  • [Cites] Ann Rheum Dis. 2005 Jun;64(6):913-20 [15550531.001]
  • [Cites] Allergol Immunopathol (Madr). 2005 Mar-Apr;33(2):69-73 [15808112.001]
  • [Cites] Am J Hematol. 2002 Mar;69(3):171-8 [11891803.001]
  • [Cites] Arthritis Rheum. 1996 May;39(5):767-72 [8639173.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1648-54 [12176884.001]
  • [Cites] Semin Oncol. 2005 Feb;32(1 Suppl 1):S19-26 [15786022.001]
  • [Cites] Rheumatology (Oxford). 2004 Oct;43(10):1309-10 [15448217.001]
  • [Cites] Leuk Lymphoma. 2006 Feb;47(2):343-6 [16321869.001]
  • [Cites] Clin Nucl Med. 2002 Feb;27(2):142-3 [11786752.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1500-6 [15632411.001]
  • [Cites] Curr Dir Autoimmun. 2005;8:140-74 [15564720.001]
  • [Cites] Ann Rheum Dis. 2006 Aug;65(8):1033-7 [16322082.001]
  • (PMID = 18270861.001).
  • [ISSN] 1559-0267
  • [Journal-full-title] Clinical reviews in allergy & immunology
  • [ISO-abbreviation] Clin Rev Allergy Immunol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


42. Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Hallek M, Engert A: Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev; 2007;(4):CD003805
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.
  • BACKGROUND: Rituximab has been shown to improve response rates and progression free survival when added to chemotherapy in patients with indolent and mantle cell lymphoma.
  • Other endpoints were overall response rate (ORR), toxicity and disease control as assessed by measures such as time to treatment failure (TTF), event free-survival (EFS), progression free-survival (PFS) and time to progression (TTP).
  • SELECTION CRITERIA: Only randomised controlled trials (RCT) comparing R-chemo with chemotherapy alone in patients with newly diagnosed or relapsed indolent lymphoma and mantle cell lymphoma (MCL) were included.
  • MAIN RESULTS: Seven randomised controlled trials involving 1943 patients with follicular lymphoma, mantle cell lymphoma, or other indolent lymphomas were included in the meta-analysis.
  • Patients treated with R-chemo had better overall survival (hazard ratio [HR] for mortality 0.65; 95% confidence interval (CI) 0.54 to 0.78), overall response (relative risk of tumour response 1.21; 95% CI 1.16 to 1.27), and disease control (HR of disease event 0.62; 95% CI 0.55 to 0.71) than patients treated with chemotherapy alone.
  • R-chemo improved overall survival in patients with follicular lymphoma (HR for mortality 0.63; 95% CI 0.51 to 0.79) and in patients with mantle cell lymphoma (HR for mortality 0.60; 95% CI 0.37 to 0.98).
  • AUTHORS' CONCLUSIONS: The systematic review demonstrated improved OS for patients with indolent lymphoma, particularly in the subgroups of follicular and in mantle cell lymphoma when treated with R-chemo compared to chemotherapy alone.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Humans. Lymphoma, Mantle-Cell / drug therapy. Randomized Controlled Trials as Topic. Rituximab. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17943799.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 67
  •  go-up   go-down


43. Forns M, Javier G, Estella J, Fernández-Delgado R, Gallego S, García-Miguel P, Indiano JM, Navajas A, Pardo N, en representación del grupo SHOP de las Sociedades Españolas de Hematología (SEHP) y Oncología Pediátricas (SEOP): [Results of the SHOP LNHB98 (LMB89) trial in pediatric patients with B-cell non-Hodgkin's lymphoma]. Med Clin (Barc); 2007 May 5;128(17):641-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of the SHOP LNHB98 (LMB89) trial in pediatric patients with B-cell non-Hodgkin's lymphoma].
  • [Transliterated title] Resultados del protocolo SHOP LNHB98 (LMB89) en pacientes de edad pediátrica afectados de linfoma no hodgkiniano de células B.
  • BACKGROUND AND OBJECTIVE: After the good results obtained by the Société Française d'Oncologie Pédiatrique (SFOP) regarding the pediatric B-type non-Hodgkin's (Burkitt and large B-cell) lymphoma and L3 leukemia, the Sociedad Española de Hematología y Oncología Pediátricas (SHOP) decided to use the same treatment protocol.
  • PATIENTS AND METHOD: Pediatric patients diagnosed with B-type non-Hodgkin's lymphoma without a previous history of malignant diseases were eligible for this study.
  • RESULTS: A total of 153 patients were considered in this multicenter, prospective and non-randomized trial (1997-2005).
  • CONCLUSIONS: The results confirm the good efficiency of the LMB89 protocol for treating B-cell lymphoma and L3 leukemia, despite having diminished the treatment intensity in the less risk groups.
  • In addition, no differences were evidenced between Burkitt and large B-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17537360.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Spain
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate; LMB89 protocol
  •  go-up   go-down


44. Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ: [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Ai Zheng; 2006 Apr;25(4):486-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: The prognosis of relapsed or refractory B-cell lymphoma is poor, with a short-term survival after conventional second-line chemotherapy.
  • Rituximab, a chimeric anti-CD20 antigen, in combination with CHOP or CHOP-like chemotherapy may improve both disease-freely survival and overall survival of naive patients, but it's role in the second-line treatment for relapsed non-Hodgkin's lymphoma (NHL) is uncertain.
  • METHODS: Clinical data of 35 patients with relapsed or refractory NHL, treated in Cancer Center of Sun Yat-sen University, were analyzed retrospectively.
  • Of the 35 patients, 19 were man, and 16 were women, with a median age of 53.5 years (ranged from 21 to 77); for ECOG performance status, 33 (94.3%) scored 0-1; for international prognostic index (IPI), 20 (57.1%) scored 0-1, 7 (20%) scored 2, 4 (11.4%) scored 3, and 4 (11.4%) scored 4-5; 23 cases of diffuse large B-cell lymphoma (DLBL) accounted for 65.7% among all subtypes.
  • The objective response rate of the 32 evaluable cases was 68.8%, with a complete remission (CR) rate of 40.6%; 3 patients achieved CR after radiotherapy following rituximab-based regimens, and 3 achieved CR after autologous hematopoietic stem cell transplantation.
  • The median follow-up time was 12.5 months (ranged from 3 to 69 months); 2 patients were lost, 10 were died (9 died of lymphoma, and 1 died of severe hepatitis), the other patients remained alive.
  • CONCLUSION: Rituximab-containing salvage regimens are effective and well tolerated, even in extensively pretreated patients with relapsed or refractory B-cell NHL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / immunology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Humans. Leukopenia / chemically induced. Male. Middle Aged. Nausea / chemically induced. Neoplasm Recurrence, Local. Prednisone / therapeutic use. Remission Induction. Rituximab. Salvage Therapy. Stem Cell Transplantation. Survival Rate. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613686.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


45. Mohrbacher A: B cell non-Hodgkin's lymphoma: rituximab safety experience. Arthritis Res Ther; 2005;7 Suppl 3:S19-25
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B cell non-Hodgkin's lymphoma: rituximab safety experience.
  • A substantial body of data supports use of rituximab as first-line and maintenance therapy for the treatment of indolent non-Hodgkin's lymphoma.
  • Since some adverse events are related to circulating tumor loads of non-Hodgkin's lymphoma, fewer events are anticipated in rheumatoid arthritis.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / pharmacology. B-Lymphocytes / drug effects. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Clinical Trials as Topic / statistics & numerical data. Humans. Rituximab

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1746-51 [12721250.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4261-7 [12377971.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Blood. 2001 Jan 1;97(1):101-6 [11133748.001]
  • [Cites] Blood. 2000 May 15;95(10):3052-6 [10807768.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):317-24 [10637245.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1851-7 [10561225.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):79-87 [10561022.001]
  • (PMID = 15960818.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 13
  • [Other-IDs] NLM/ PMC2833973
  •  go-up   go-down


46. Magić Z, Novković T, Cikota B, Tasić-Radić O, Tarabar O, Stamatović D: Genetic alterations in B-cell non-Hodgkin's lymphoma. Vojnosanit Pregl; 2005 Feb;62(2):87-96

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations in B-cell non-Hodgkin's lymphoma.
  • BACKGROUND: Although the patients with diagnosed B-NHL are classified into the same disease stage on the basis of clinical, histopathological, and immunological parameters, they respond significantly different to the applied treatment.
  • This points out the possibility that within the same group of lymphoma there are different diseases at molecular level.
  • For that reason many studies deal with the detection of gene alterations in lymphomas to provide a better framework for diagnosis and treatment of these hematological malignancies.
  • METHODS: Formalin fixed and paraffin embedded lymph node tissues from 45 patients were examined by different PCR techniques for the presence of IgH and TCR gamma gene rearrangement; K-ras and H-ras mutations; c-myc amplification and bcl-2 translocation.
  • There were 34 cases of B-cell non-Hodgkin's lymphoma (B-NHL), 5 cases of T-cell non-Hodgkin's lymphoma (T-NHL) and 6 cases of chronic lymphadenitis (CL).
  • The mononuclear cell fraction of the peripheral blood of 12 patients with B-NHL was analyzed for the presence of monoclonality at the time of diagnosis and in 3 to 6 months time intervals after an autologous bone marrow transplantation (BMT).
  • RESULTS: The monoclonality of B-lymphocytes, as evidenced by DNA fragment length homogeneity, was detected in 88 % (30/34) of B-NHL, but never in CL, T-NHL, or in normal PBL.
  • Bcl-2 translocation was detected in 7/31 (22.6%) B-NHL specimens, c-myc amplification 9/31 (29%, all were more than doubled), K-ras mutations in 1/31 (3.23%) and H-ras mutations in 2/31 (6.45%) of the examined B-NHL samples.
  • All the patients (12) with B-NHL had dominant clone of B-lymphocyte in the peripheral blood at the time of diagnosis while only in 2 of 12 patients MRD was detected 3 or 6 months after BMT.
  • This technique is also very effecient for tracking minimal residual disease in lymphomas and leukemias and for monitoring clonal evolution in acute and chronic lymphoblastic leukemias and lymphomas.
  • [MeSH-major] Lymphoma, B-Cell / genetics
  • [MeSH-minor] Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Genetic Markers. Humans. Point Mutation. Proto-Oncogenes / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15787160.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Yugoslavia
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


47. Levine B, Sinha SC, Kroemer G: Bcl-2 family members: Dual regulators of apoptosis and autophagy. Autophagy; 2008 Jul 01;4(5):600-606
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 family members: Dual regulators of apoptosis and autophagy.
  • In normal conditions, Beclin 1 is bound to and inhibited by Bcl-2 or the Bcl-2 homolog Bcl-X<sub>L</sub>.
  • This interaction involves a Bcl-2 homology 3 (BH3) domain in Beclin 1 and the BH3 binding groove of Bcl-2/Bcl-X<sub>L</sub>.
  • Other proteins containing BH3 domains, called BH3-only proteins, can competitively disrupt the interaction between Beclin 1 and Bcl-2/Bcl-X<sub>L</sub> to induce autophagy.
  • Nutrient starvation, which is a potent physiologic inducer of autophagy, can stimulate the dissociation of Beclin 1 from its inhibitors, either by activating BH3-only proteins (such as Bad) or by posttranslational modifications of Bcl-2 (such as phosphorylation) that may reduce its affinity for Beclin 1 and BH3-only proteins.
  • Thus, anti-apoptotic Bcl-2 family members and pro-apoptotic BH3-only proteins may participate in the inhibition and induction of autophagy, respectively.
  • This hitherto neglected crosstalk between the core machineries regulating autophagy and apoptosis may redefine the role of Bcl-2 family proteins in oncogenesis and tumor progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28186856.001).
  • [ISSN] 1554-8635
  • [Journal-full-title] Autophagy
  • [ISO-abbreviation] Autophagy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Lansigan F, Cooper D, Seropian S, Foss F: Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience. J Clin Oncol; 2009 May 20;27(15_suppl):8558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience.
  • : 8558 Aggressive T-cell lymphomas (ATCL) represent 10-15% of non-Hodgkin lymphoma and have a worse prognosis than aggressive B-cell lymphomas.
  • Both autologous (Auto) and allogeneic (Allo) stem cell transplantation have been used as consolidation in first remission and at relapse, but the role of transplantation has not been clearly defined.
  • The Allo group consisted of 4 PTCLu, 3 angioimmunoblastic(AITL), 2 panniculitis-like, 2 cutaneous(CTCL) with large cell transformation, 2 NK-cell, 2 anaplastic large cell(ALCL), 1 hepatosplenic, 1 enteropathic, and 1 refractory CTCL.
  • The Auto group consisted of 6 PTCLu, 12 ALCL (5 Alk+, 5 Alk-, 2 Alk unk), 4 AITL, 1 CTCL with transformation, and 1 T-lymphoblastic lymphoma.
  • Median time from diagnosis to Allo or Auto was 18 and 8mo, respectively.
  • The non-relapse mortality was 33%(Allo) and 8%(Auto).
  • For patients with resistant or relapsed disease, Allo should be strongly considered rather than Auto.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960993.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Kolokotronis A, Konstantinou N, Christakis I, Papadimitriou P, Matiakis A, Zaraboukas T, Antoniades D: Localized B-cell non-Hodgkin's lymphoma of oral cavity and maxillofacial region: a clinical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Mar;99(3):303-10
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized B-cell non-Hodgkin's lymphoma of oral cavity and maxillofacial region: a clinical study.
  • OBJECTIVE: Non-Hodgkin's lymphomas (NHL) are the third most common group of malignant lesions in the oral cavity and maxillofacial region.
  • Most such lymphomas have been shown to be predominantly of B-lineage.
  • The purpose of the present study is to analyze the clinical signs and symptoms and the clinical staging of B-cell NHL of this region.
  • STUDY DESIGN: Eighteen adults, with B-cell NHL manifestations of the oral cavity and maxillofacial region, were available for this study.
  • The clinical stage according to the Ann Arbor system was assessed by history, physical, and laboratory examination.
  • Histologic diagnosis was based on the WHO classification of tumors.
  • At the time of the disease presentation, according to the Ann Arbor system, 11 patients were in stage IE, 2 patients in stage IIE, 2 patients in stage IIIE, 1 patient in stage IVE, and 2 patients in stage IV.
  • The typical clinical appearance was a painless local mass lateral or bilateral.
  • All the different histologic types may be observed, but the most frequently encountered is the diffuse large type.
  • CONCLUSIONS: The B-cell NHL may involve both osseous and soft tissues of the oral cavity and maxillofacial region.
  • The typical clinical appearance is a painless local mass lateral or bilateral.
  • According to the Ann Arbor system, the majority of the cases at the time of diagnosis are in stage I or II.
  • Most patients have high grade disease.
  • All the different histologic types may be observed, but the most frequently encountered is the diffuse large type.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15716836.001).
  • [ISSN] 1079-2104
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Piskin O, Alacacioglu I, Ozkal S, Ozcan MA, Demirkan F, Hayri Ozsan G, Kargi A, Undar B: A patient with diffuse large B-cell non-Hodgkin's lymphoma and AA type amyloidosis. J BUON; 2008 Jan-Mar;13(1):113-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with diffuse large B-cell non-Hodgkin's lymphoma and AA type amyloidosis.
  • AA-type amyloidosis is a consequence of a long-standing systemic inflammation and is not associated with a monoclonal protein or clonal bone marrow plasma cells.
  • Although the association of non-Hodgkin's lymphoma (NHL) with AL-type amyloidosis is well known and patients with Hodgkin's lymphoma with AA amyloidosis have been described, AA-type amyloidosis with NHL is extremely infrequent.
  • [MeSH-major] Amyloidosis / etiology. Lymphoma, Large B-Cell, Diffuse / complications. Serum Amyloid A Protein / metabolism


51. Sapra P, Kraft P, Mehlig M, Malaby J, Zhao H, Greenberger LM, Horak ID: Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma. Haematologica; 2009 Oct;94(10):1456-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma.
  • Examination of the clinical utility of SN38 (10-hydroxy-7-ethyl-camptothecin), the active metabolite of CPT-11, has not been possible to date due to poor solubility of SN38.
  • Here we evaluated the activity of EZN-2208, a water-soluble polyethyleneglycol-SN38 conjugate, in pre-clinical models of Burkitt's non-Hodgkin's lymphoma (NHL) (Raji and Daudi), and follicular NHL (DoHH2).
  • In both an early-disease Raji model and an advanced-disease Daudi model, treatment with multiple doses of EZN-2208 resulted in 90% and 100% cures of animals, respectively (cure defined as no sign of tumors by gross observations at the termination of study).
  • The excellent therapeutic efficacy of EZN-2208 in several B-cell NHL xenograft models merits its evaluation in the clinic for lymphoid malignancies.
  • [MeSH-major] Camptothecin / analogs & derivatives. Lymphoma, B-Cell / drug therapy. Polyethylene Glycols / chemistry. Polyethylene Glycols / therapeutic use. Xenograft Model Antitumor Assays
  • [MeSH-minor] Animals. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology. Cell Line, Tumor. Female. Humans. Mice. Mice, SCID

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6845-8 [15466170.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1475-82 [14983893.001]
  • [Cites] Br J Cancer. 1994 Oct;70(4):771-4 [7917938.001]
  • [Cites] Jpn J Clin Oncol. 1996 Dec;26(6):455-60 [9001351.001]
  • [Cites] Clin Pharmacokinet. 1997 Oct;33(4):245-59 [9342501.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1888-96 [18347192.001]
  • [Cites] Bioconjug Chem. 2008 Apr;19(4):849-59 [18370417.001]
  • [Cites] Br J Haematol. 2008 May;141(5):676-80 [18422776.001]
  • [Cites] Clin Adv Hematol Oncol. 2008 Jun;6(6):437-45 [18567989.001]
  • [Cites] Ann Hematol. 2001 Jul;80(7):411-6 [11529467.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):594-600 [11857289.001]
  • [Cites] Oncology (Williston Park). 2002 Aug;16(8 Suppl 7):27-31 [12199630.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):5-15 [12506163.001]
  • [Cites] Mol Cancer Ther. 2003 Mar;2(3):235-43 [12657718.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 2:67-71 [7515649.001]
  • (PMID = 19794091.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / EZN-2208; 0 / SN38-Glu; 30IQX730WE / Polyethylene Glycols; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2754965
  •  go-up   go-down


52. Lumia D, Laganà D, Verna E, Mangini M, Canì A, Carrafiello G, Fugazzola C: Recurrence of intracardiac large B-cell non-Hodgkin's lymphoma (NHL) encasing and nearly obliterating the right coronary artery: a case report. Minerva Chir; 2010 Jun;65(3):383-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of intracardiac large B-cell non-Hodgkin's lymphoma (NHL) encasing and nearly obliterating the right coronary artery: a case report.
  • Among malignant tumors of the heart, primary malignant lymphomas are unusual and they are typically non-Hodgkin's B-cell cancers.
  • A 73-year-old man affected by non-Hodgkin lymphoma (NHL) treated with four cycle of chemotherapy and radiotherapy was admitted to the Emergency Department for chest pain.
  • [MeSH-major] Coronary Stenosis / etiology. Heart Neoplasms / complications. Lymphoma, Large B-Cell, Diffuse / complications. Neoplasm Recurrence, Local / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20668424.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


53. Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Gobbi PG, Angrilli F, Brugiatelli M, Musto P, Federico M: Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study. Haematologica; 2008 Sep;93(9):1335-42
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study.
  • BACKGROUND: Improved treatment has increased the life expectancy of patients with non-Hodgkin's lymphoma, but few studies have addressed the issue of second cancer in patients treated for diffuse large B-cell lymphoma.
  • DESIGN AND METHODS: We evaluated a cohort of 1280 patients with diffuse large B-cell lymphoma who were first treated between 1988 and 2003.
  • We utilized the central database of the Gruppo Italiano Studio Linfomi, which includes data on demographics, clinical characteristics, laboratory parameters, treatment and follow-up of all patients with non-Hodgkin's lymphoma enrolled in clinical trials.
  • A multivariate analysis showed that older age at the time of diagnosis of lymphoma had a negative influence on the time free of second tumors.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / therapy. Neoplasms, Second Primary / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698083.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


54. Uzuka Y, Saitou Y, Saitou K, Suzuki S, Yamaguchi M: [Results of dose-intense, dose-impact weekly combination chemotherapy with rituximab for patients with CD 20-positive B-cell non-Hodgkin's lymphoma]. Gan To Kagaku Ryoho; 2007 Jul;34(7):1085-90
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of dose-intense, dose-impact weekly combination chemotherapy with rituximab for patients with CD 20-positive B-cell non-Hodgkin's lymphoma].
  • Excellent results were reported for dose-dense and dose-intense weekly combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, etoposide and additional ara-C) (CHOEA-7) and with rituximab (RCHOEA-7), for patients with CD 20-positive non-Hodgkin's lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antigens, CD20 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637545.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


55. Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT: Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clin Cancer Res; 2010 May 15;16(10):2760-8
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
  • PURPOSE: Non-Hodgkin's lymphoma (NHL) is the sixth most common cause of cancer death in the U.S.
  • EXPERIMENTAL DESIGN: In vitro cytotoxicity of IL-PLD and PLD was assessed in CD22-positive and CD22-negative cell lines.
  • RESULTS: IL-PLD improved cytotoxicity over PLD only in CD22-positive cells.
  • [MeSH-major] Antibodies, Monoclonal / pharmacokinetics. Antineoplastic Agents / pharmacokinetics. Doxorubicin / analogs & derivatives. Lymphoma, B-Cell / drug therapy. Polyethylene Glycols / pharmacokinetics. Sialic Acid Binding Ig-like Lectin 2 / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AACR.
  • (PMID = 20460479.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Liposomes; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


56. Liu L, Yao JX, Ding Q, Huang SA: [CD4+ CD25high regulatory T cells in peripheral blood of patients with B cell non-Hodgkin's lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb;14(1):119-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CD4+ CD25high regulatory T cells in peripheral blood of patients with B cell non-Hodgkin's lymphoma].
  • This study was aimed to analyze the proportion of T cell subsets, CD4(+) CD25(high) regulating T cells (Tr) in peripheral blood of B-NHL patients and their change regularity, and to investigate the immunosuppression mechanism and influence of chemotherapy on immunosuppression function of B-NHL patients.
  • By using monoclonal antibodies, the blood samples were evaluated with the flow cytometry for lymphocyte subsets and Tr cells.
  • The results showed that the proportion of CD3(+) and CD4(+) T cells, and the ratio of CD4/CD8 in patients with B-NHL group was significantly less than those in the healthy controls, i.e. (68.33 +/- 15.27)% versus (72.06 +/- 9.26)%; (34.47 +/- 12.84)% versus (42.45 +/- 9.2)%; 1.36 +/- 0.26 versus 1.92 +/- 0.20, but the prevalence of the CD4(+) CD25(high) Tr cells was significantly higher than those in the healthy group [(4.10 +/- 1.21)% versus (2.04 +/- 1.03)%, P < 0.001].
  • The ratio of CD4/CD8 in chemotherapy group was lower than that in control, but the proportion of CD4(+) CD25(high) Treg cells in chemotherapy group was higher than those before chemo-/radio-therapy and the control.
  • It is concluded that the relative increase of CD4(+) CD25(high) Tr cells in peripheral blood of B-NHL patients may be related to immunosuppression and tumor progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16584606.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Interleukin-2 Receptor alpha Subunit
  •  go-up   go-down


57. Winter JN, Inwards DJ, Spies S, Wiseman G, Patton D, Erwin W, Rademaker AW, Weitner BB, Williams SF, Tallman MS, Micallef I, Mehta J, Singhal S, Evens AM, Zimmer M, Molina A, White CA, Gordon LI: Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2009 Apr 1;27(10):1653-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.
  • PATIENTS AND METHODS: Eligible patients had relapsed or refractory CD20+ non-Hodgkin's lymphoma (NHL).

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. PODOFILOX .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 1999 Nov;15(5):1017-25 [10536187.001]
  • [Cites] Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):212-8 [21575926.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1588-93 [10688812.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1557-62 [11301405.001]
  • [Cites] Bone Marrow Transplant. 2001 Mar;27(6):593-9 [11319588.001]
  • [Cites] J Clin Oncol. 2001 Oct 1;19(19):3918-28 [11579112.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2453-63 [12011122.001]
  • [Cites] J Nucl Med. 2003 Mar;44(3):465-74 [12621016.001]
  • [Cites] J Nucl Med. 2004 Jun;45(6):1059-64 [15181141.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1504-9 [15367411.001]
  • [Cites] Int J Rad Appl Instrum B. 1991;18(4):369-81 [1864725.001]
  • [Cites] N Engl J Med. 1993 Oct 21;329(17):1219-24 [7692295.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):588-95 [7884420.001]
  • [Cites] Lancet. 1995 Aug 5;346(8971):336-40 [7623531.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3270-8 [9779701.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):461-7 [15534357.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1359-65 [15939712.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 1):59-65 [16399587.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4):534-40 [17379063.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4285-92 [17709799.001]
  • [Cites] Semin Hematol. 2007 Oct;44(4):234-45 [17961722.001]
  • [Cites] Br J Haematol. 2007 Nov;139(4):590-9 [17979944.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1533-48 [18024402.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):90-5 [18025438.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5175-82 [18854569.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • (PMID = 19255322.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA060553; United States / NCI NIH HHS / CA / P30 CA 060553
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / ibritumomab tiuxetan; 04079A1RDZ / Cytarabine; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ PMC2668971
  •  go-up   go-down


58. Ferrara F, Viola A, Copia C, Schiavone EM, Celentano M, Pollio F, D'Amico MR, Palmieri S: Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation. Hematol Oncol; 2006 Jun;24(2):73-7
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation.
  • Forty patients with relapsed diffuse large B cell lymphoma (DLBCL) autografted in partial response (PR) (n = 23) or in refractory relapse (RR) (n = 17) achieved complete remission (CR) after autologous stem cell transplantation (ASCT).
  • These data demonstrate that CR achieved after ASCT in DLBCL patients who are refractory to previous salvage therapy does not result in long-term disease control.
  • [MeSH-major] Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Stem Cell Transplantation
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Recurrence. Retrospective Studies. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550628.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Venizelos J, Tamiolakis D, Nikolaidou S, Lambropoulou M, Alexiadis G, Papadopoulos N: Concurrent low grade B-cell non-Hodgkin's lymphoma of MALT type arising in the large intestine, small intestine and stomach. Chirurgia (Bucur); 2007 Jan-Feb;102(1):99-101
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent low grade B-cell non-Hodgkin's lymphoma of MALT type arising in the large intestine, small intestine and stomach.
  • Low-grade non-Hodgkin's lymphomas (NHL) of mucosa associated lymphoid tissue (MALT) are indolent neoplasms that, although tending to remain localized for many years, may spread to other mucosal sites.
  • Despite increasing identification of concurrent gastric and intestinal lymphoma of MALT type, the clonal relationship between the tumors and their sequential development are poorly understood.
  • It is also unknown whether the development of these concurrent tumors is closely associated with direct antigen stimulation, which is thought to play an important role in the clonal expansion of low grade MALT lymphomas.
  • The most important function of B-cells is production of specific antibodies.
  • This is largely achieved during B-cell development by recombination of the Ig heavy chain variable (V), diversity (D), and joining (J) segments and hypermutation of the rearranged gene.
  • The rearranged Ig genes of a mature B-cell record much of its evolution history.
  • We report a case of synchronous development of intestinal and gastric low grade MALT lymphomas in a 70 years old female and discuss their possible clonal relationship and sequential appearance.
  • [MeSH-major] Intestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Clone Cells / pathology. Colon / pathology. Female. Humans. Intestine, Small / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Stomach / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410739.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


60. Cikota BM, Tukić LJ, Tarabar OT, Magić ZM: Detection of t(14;18), P53 and RAS gene mutations and quantification of residual disease in patients with B-cell non-Hodgkin's lymphoma. J Exp Clin Cancer Res; 2007 Dec;26(4):535-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of t(14;18), P53 and RAS gene mutations and quantification of residual disease in patients with B-cell non-Hodgkin's lymphoma.
  • PCR analysis has been demonstrated as a valuable tool for detection of minimal residual disease (MRD) in lymphoid malignancies.
  • However, the finding that patients with evidence of MRD sometimes remain in long-lasting remission directs further investigations toward biology of residual disease and/or quantification of MRD level.
  • The study included 40 B-NHL patients--13/40 patients with high- (HG) and 27/40 with low-grade (LG) lymphoma.
  • Seven patients achieved partial clinical remission (PR) and 33 patients achieved complete clinical remission (CCR) after chemotherapy.
  • Peripheral blood samples were analyzed for MRD at up to ten follow-up points while samples of MRD+ patients and patients who achieved partial clinical response after therapy were further analyzed for the presence of t(14;18) and P53 and RAS genes mutations.
  • The study implies that MRD level, measured at one follow-up point, does not correlate with clinical outcome.
  • The measurement of MRD level sequentially, at different follow-up points, seems to be a better parameter for the prediction of disease course.
  • [MeSH-major] Genes, p53. Genes, ras. Lymphoma, B-Cell / genetics. Mutation. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Female. Humans. Male. Middle Aged. Neoplasm, Residual. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365550.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


61. Gerrard M, Waxman I, Sposto R, Auperin A, Harrison L, Pinkerton R, Perkins SL, McCarthy K, Raphael M, Patte C, Cairo MS, FAB/LMB 96 Trial: Association of primary mediastinal B-cell lymphoma (PMBL) in children (C) and adolescents (A) with a significantly inferior prognosis: Final results of the FAB/LMB 96 trial. J Clin Oncol; 2009 May 20;27(15_suppl):10001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of primary mediastinal B-cell lymphoma (PMBL) in children (C) and adolescents (A) with a significantly inferior prognosis: Final results of the FAB/LMB 96 trial.
  • : 10001 Background: Single pediatric cooperative group studies have demonstrated an EFS ranging from 65 - 75% in C & A with large cell lymphomas arising in the mediastinum (Lones/Cairo et al, J Clin Oncol, 2000; Burkhardt/Reiter et al, Br J Haematol, 2005; Seidman/Reiter et al, J Clin Oncol, 2003).
  • Recently, Staudt and Shipp have independently demonstrated that following gene expression profiling by oligonucleotide microarray that PMBL resembles more like classical Hodgkin lymphoma than diffuse large B-cell lymphoma with enhanced NF-κB pathway gene expression (Rosenwald et al, J Exp Med, 2003; Abramson et al, Blood, 2005).
  • RESULTS: There were 528 patients with stage III/IV disease treated on group B therapy on FAB/LMB 96 resulting in a 2 yr EFS of 84% (CI<sub>95</sub>: 82-86%).
  • 5 yr EFS was significantly inferior compared to the remainder of the other patients with stage III disease treated on group B therapy (54%: CI<sub>95</sub> 38-68% vs 85%: CI<sub>95</sub> 81-88%) (p < 0.001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962546.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Gratzinger D, Advani R, Zhao S, Talreja N, Tibshirani RJ, Horning SJ, Levy R, Lossos IS, Gascoyne RD, Natkunam Y: Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP). J Clin Oncol; 2009 May 20;27(15_suppl):8581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP).
  • : 8581 Background: Diffuse large B cell lymphoma (DLBCL) cells coexpress VEGF, VEGFR1 and VEGFR2.
  • METHODS: 162 pts with de novo DLBCL treated with R-CHOP and median followup of 44 months were evaluated retrospectively with immunohistochemistry on tissue microarrays.
  • Scoring: VEGF, VEGFR1, VEGFR2, and phosphoVEGFR2 (pVEGFR2) in lymphoma cells (categorical variable) <5%, none; 5-30%, weak; >30%, strong.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962266.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Yoo C, Sohn B, Kim J, Yoon D, Huh J, Kim S, Lee D, Kim S, Lee J, Suh C: The prognostic significance of the number of extranodal sites in the patients with disseminated diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol; 2009 May 20;27(15_suppl):8570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic significance of the number of extranodal sites in the patients with disseminated diffuse large B-cell lymphoma treated with R-CHOP.
  • : 8570 Background: The combination of rituximab and CHOP chemotherapy (R-CHOP) has improved survival of patients with diffuse large B-cell lymphoma (DLBCL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961016.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Gisselbrecht C, Glass B, Mounier N, Gill D, Linch D, Trneny M, Bosly A, Shpilberg O, Ketterer N, Moskowitz C, Schmitz N: R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol; 2009 May 20;27(15_suppl):8509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study.
  • : 8509 Background: Salvage chemotherapy followed by high dose therapy and autologous stem cell transplantation (ASCT) is the standard of treatment for chemosensitive relapses in diffuse large B cell lymphoma.
  • Patients with prior exposure to rituximab had more refractory disease and adverse prognostic factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960863.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Nabil IN Jr, Allam W, Alaoui K, Errihani H: Primary nasopharyngeal non Hodgkin lymphoma: A retrospective investigation of 26 patients. J Clin Oncol; 2009 May 20;27(15_suppl):e19552

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary nasopharyngeal non Hodgkin lymphoma: A retrospective investigation of 26 patients.
  • : e19552 Background: Primary nasopharyngeal non-Hodgkin lymphoma (NNHL) was uncommon.
  • In this retrospective study we report our experience dealing with this disease at the National Institute of Oncology.
  • METHODS: We retrospectively analyzed various characteristics of Primary NNHL: patient demographics, clinical and histological diagnosis, disease stage, treatment effects and outcome, in 26 patients treated at our institution between January 2001 and December 2007.
  • The major symptoms at first diagnosis were: nasal obstruction (88.6%), hypoacousia (88.4%), epistaxis (33.3%) and rhinorrhea (15.3%).
  • Clinical examination founded bilateral cervical lymph nodes in 17 cases (65%).
  • Histological analysis showed follicular lymphoma in 7 cases (26.9%), large B-cell lymphoma in 11 cases (42,3%) and T lymphoma in 4 cases ( 15,3%).
  • At the end of total treatment, 18 patients (69.2%) achieved complete response and remained disease free while 4 (15.4%) achieved partial response (>70%) and 4 (15.4%) were progressive (these patients received second line chemotherapy).
  • After 110 months median flow-up, median disease free and overall survival were not reached.
  • CONCLUSIONS: From our study and from the literature, we conclude that histological characteristics, principle of treatment and outcome of primary NNHL patients are similar to that of patients with nodal lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961093.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Sohn B, Yoon D, Kim S, Lee D, Kim S, Huh J, Lee J, Suh C: Outcomes in patients with primary gastric diffuse large B-cell lymphoma after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e19543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes in patients with primary gastric diffuse large B-cell lymphoma after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy.
  • : e19543 Background: The optimal therapy for primary gastric diffuse large B- cell lymphoma (DLBCL) still needs to be defined.
  • METHODS: We searched AMC Registry for Non-Hodgkin's Lymphoma and found 26 patients with primary gastric DLBCL, who received R-CHOP as first-line chemotherapy.
  • Ten of 26 patients had localized disease.
  • Remaining patients had disseminated disease.
  • After analyses of 10 patients with localized disease, we found that these patients had received a total 38 cycles, with a median of 3 cycles per patient.
  • In patients with localized disease, CR was observed in 10 of 10 patients (100%), and both 3-year EFS and OS was 100% (10 of 10 patients).
  • In analyses with 16 patients with disseminated disease, all patients had received a total 91 cycles, with a median of 6 cycles per patient.
  • CR after R-CHOP treatment was observed in 10 of 16 patients (62.5%), partial response in 3 patients, stable disease in 1 patient, and progressive disease in 1 patient.
  • Three-year EFS and OS was 61.1% and 57.8% in patients with disseminated disease.
  • Combination with rituximab in CHOP regimen showed excellent prognosis especially in patients with localized disease.
  • In localized disease, CR was 100%, 3-year EFS and OS was 100%.
  • In disseminated disease, CR was 62.5%, 3-year EFS and OS was 61.1% and 57.8%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960994.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Zhang M, Huck J, Hyer M, Ecsedy J, Manfredi M: Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. J Clin Oncol; 2009 May 20;27(15_suppl):8553

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models.
  • : 8553 Background: Aurora A kinase is a serine/threonine protein kinase that is essential for the successful transit of cells through mitosis.
  • In this study we explored the anti-tumor effect of MLN8237 in vivo in pre-clinical models of human Diffuse Large B-cell Lymphoma (DLBCL) both as a single agent and in combination with the anti-CD20 monoclonal antibody Rituximab.
  • In two of the models (Ly19 & WSU) the tumor cells expressed a constitutively active luciferase, enabling tumor burden analysis in either a subcutaneous or disseminated setting.
  • In the primary lymphoma model, MLN8237(10-20mg/kg) caused a significant anti-tumor effect during treatment period (TGI = 83-95%).
  • MLN8237 is currently being tested as a single agent in a phase I clinical trail in patients with DLBCL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960986.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Park SC, Jeong SH, Kim J, Han CJ, Kim YC, Choi KS, Cho JH, Lee M, Jung HH, Ki SS, Chang YH, Lee SS, Park YH, Lee KH: High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin's lymphoma in Korea. J Med Virol; 2008 Jun;80(6):960-6
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin's lymphoma in Korea.
  • This study assessed the association of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection with non-Hodgkin's lymphoma in a highly HBV-endemic area.
  • The prevalence of either HBV or HCV infection in 235 patients with non-Hodgkin's lymphoma was compared with that of an age- and sex-matched hospital control group of 235 patients.
  • The prevalence of HBV infection was higher in B-cell non-Hodgkin's lymphoma (15.5%) than control (8.1%), but the prevalence of HCV infection in the non-Hodgkin's lymphoma patients (2.1%) and control group (3%) was similar.
  • HBV prevalence increased significantly with age in the B-cell non-Hodgkin's lymphoma patients.
  • The presence of HBV proteins and DNA in lymphoma tissues and peripheral blood mononuclear cells (PBMCs) from HBV-infected non-Hodgkin's lymphoma patients was also investigated using immunohistochemistry and PCR.
  • HBV DNA was frequently detected in PBMCs from HBV-infected non-Hodgkin's lymphoma patients, but HBV antigens were not.
  • Therefore, HBV infection, but not HCV infection, was associated with B-cell non-Hodgkin's lymphoma in Korea, suggesting a possible role for HBV in the development of non-Hodgkin's lymphoma.
  • [MeSH-major] Hepatitis B / complications. Hepatitis B / epidemiology. Lymphoma, B-Cell / complications. Lymphoma, Non-Hodgkin / complications

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18428141.001).
  • [ISSN] 0146-6615
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Hepatitis B Core Antigens; 0 / Hepatitis B Surface Antigens
  •  go-up   go-down


69. Vose J, Loberiza F, Armitage J, Bierman P, Bociek R, Dornan D: Effects of FCGR3A and FCGR2A polymorphisms on outcomes of patients with diffuse large B-cell lymphoma treated with CHOP-like chemotherapy versus CHOP-rituximab. J Clin Oncol; 2009 May 20;27(15_suppl):8567

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of FCGR3A and FCGR2A polymorphisms on outcomes of patients with diffuse large B-cell lymphoma treated with CHOP-like chemotherapy versus CHOP-rituximab.
  • : 8567 Background: The addition of rituximab to cyclophosphamide/ doxorubicin/ vincristine/ prednisone (R-CHOP) therapy for diffuse large B-cell lymphoma (DLBCL) has significantly improved the outcome for many patients (pts).
  • In a multivariate analysis for risk of progression or death: FCGR2A : H/H vs. H/R or R/R by treatment type: CHOP-like [RR 0.63 (95% CI 0.37-1.08), p=0.10] and R-CHOP [RR 0.59 (0.36-0.96), p=0.04] and for FCGR3A V/V vs. F/V or F/F by treatment arm: CHOP-like [RR 0.75 (0.36-1.54), p=0.43] and R-CHOP [RR 2.28(0.70-7.44), p=0.17].
  • However, our study also suggests that a trend toward association of certain polymorphisms with clinical outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961024.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Gaffar HA, Elfayomy A, Elmaghraby A, Elnemr MM, Elsawy WH: bcl-2 expression and possibility of bladder preservation using combined modality treatment in muscle-invasive transtional cell carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16133

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] bcl-2 expression and possibility of bladder preservation using combined modality treatment in muscle-invasive transtional cell carcinoma.
  • To evaluate the combined modality treatment and selective bladder preservation and to evaluate BCL-2 expression that may predict treatment response and survival.
  • METHODS: 66 eligible patients with T2-4a NxM0 transitional cell carcinoma received two courses of gemcitabine and cisplatin followed by 45 Gy of pelvic radiotherapy in 1.8 Gy fractions with concomitant cisplatin.
  • Immunohistochemistry was used to assess the tumor cell expression of BCL-2.
  • Bcl-2 was expressed in 35 (53%) of the patients.
  • Bcl-2 immunoreactivity was inversely correlated with of histological grade (p = 0.0232) and was not correlated with gender distribution (p = 0.4666), the clinical stage (T) (p = 0.4325) or response to treatment (p = 0.6234).
  • No significant difference was noted between the cause-specific survival rate of patients with positive Bcl-2 expression and those with negative BCL-2 expression.
  • CONCLUSIONS: this combined approach of chemotherapy and radiation therapy with bladder preservation should be considered as an option for muscle-invasive transitional cell carcinoma of bladder.
  • Assessment of Bcl-2 protein expression may be used to predict a clinical response to this combined modality approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963367.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Lopez R, Gallardo E, Ruibal A, Leon L, Sanchez-Salmon A, Abdulkader I, Gude F, Curiel T, Barandela J, Gayoso L: HIF expression and Max-SUV-18F-FDG-PET in non-small cell lung cancer (NSCLC) patients. J Clin Oncol; 2009 May 20;27(15_suppl):e22010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIF expression and Max-SUV-18F-FDG-PET in non-small cell lung cancer (NSCLC) patients.
  • WI) to construct a TMA block, according to conventional protocols for the study of immunohistochemical expression of HIF-1α, HIF-2 α, EGFR, bcl-2, MIB1, p16, p63 and cyclins A, B1, D1 and D3.
  • Sections were scored as positive if >10% of cells stained positively.
  • Staining patterns were correlated to clinical variables.
  • RESULTS: HIF- 1α expression was observed in 84/96 patients (34/39 adenocarcinomas and 50/57 squamous cell carcinomas), however it did not correlate with clinical stage (I-II: 41/45 vs III-IV: 44/51).
  • HIF-2 α expression was observed in 60/103 cases (27/42 adenocarcinomas and 33/61 squamous cell carcinomas) and it did not correlate with clinical stage ((I-II: 28/45 vs III-IV: 32/57).
  • After multivariate analysis, only the clinical stage (RR: 2,2) was a prognostic factor. CONCLUSIONS:.
  • 1) HIF-1α and HIF-2 α expressions are frequent in patients with NSCLCs and it did not correlate with clinical stage;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963184.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Psyrri D, Pectasides E, Weinberger P, Sasaki C, Burtness B, Fountzilas G: Outcome and molecular features of head and neck squamous cell carcinomas (HNSCC) bearing a p16 high phenotype. J Clin Oncol; 2009 May 20;27(15_suppl):6031

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and molecular features of head and neck squamous cell carcinomas (HNSCC) bearing a p16 high phenotype.
  • : 6031 Background: We have previously demonstrated that p16 expression defines a biologically distinct subgroup of oropharyngeal squamous cell cancers (OSCC).
  • Protein expression levels for a panel of 13 markers (EGFR, MET, STAT 3, ERK 1/2, pAkt, PI3Kp85, PI3Kp110, PTEN, p53, Bcl-2, E-cadherin, β-catenin, NFκB) were analyzed using AQUA.
  • p16 positive tumors also expressed higher levels of PTEN (p = 0.0009), PI3Kp110 (p = 0.03), NFκB (p = 0.007), and Bcl-2 (p = 0.005).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962428.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Ritesh P, Pahuja S, Chavez J, Braddy W, Skipper M, Bernstein ZP, Chanan-Khan A, Ramanarayanan J, Czuczman MS, Hernandez-Ilizaliturri FJ: Correlation of surface expression of CD11b or CD32 in polymorphonuclear cells (PMNs) and CD69 in natural killer cells (NK) with progression-free survival (PFS) following chemoimmunotherapy with rituximab and liposomal doxorubicin (LD) in patients (pts) with relapsed or refractory B-cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8583

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of surface expression of CD11b or CD32 in polymorphonuclear cells (PMNs) and CD69 in natural killer cells (NK) with progression-free survival (PFS) following chemoimmunotherapy with rituximab and liposomal doxorubicin (LD) in patients (pts) with relapsed or refractory B-cell lymphoma.
  • FcγRIIIa polymorphisms have been associated with clinical responses to rituximab.
  • To this end, we prospectively studied the pre-treatment quality and function of PMNs and NK cells from pts with refractory/relapsed B-cell lymphomas in a Phase I/II trial.
  • Forty-two B-cell lymphoma patients pts completed treatment.
  • Surface expression of CD11b and CD32 in the PMN's correlated with a longer PFS (P = 0.040 and P = 0.015, respectively).There was a non-statistically significant trend towards an improved in PFS in those patients whom their PBMC's exhibited a higher degree of ex-vivo rituximab ADCC.
  • Our data suggest that R+LD is a safe and effective regimen and that the quality of the immune system prior to a chemo-immunotherapy regimen may play a role in clinical outcomes, specifically the expression of CD11b and CD32 in PMNs or CD69 in NKcells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962271.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Hensel M, Goetzenich A, Hanhoff N, Wolf E, Knechten H, Mosthaf F: Cancer incidence in HIV-positive patients in Germany: A nation-wide survey from 2000 to 2007. J Clin Oncol; 2009 May 20;27(15_suppl):e22115

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to gather data on the epidemiology of AIDS-defining (AD) and non-AIDS-defining (NAD) malignancies in HIV-positive patients (pts) in Germany in the past decade.
  • The questionnaire requested information on all malignancies in HIV-positive pts, tumor stage, CDC (Center for Disease Control)-stage of the HIV infection, sex, treatment and clinical course.
  • The majority of pts had advanced HIV-disease (CDC stage C3), but the proportion of pts with stage C3 decreased from 58% in 2000 to 36.8% in 2007.
  • 253 (45.8%) were AD as follows: 132 Kaposi Sarcomas, 109 aggressive B-cell lymphomas, 12 invasive cervix carcinomas.
  • The B-cell lymphomas further included 28 Burkitt's lymphomas, 30 DLBCL, 9 Castleman diseases, 8 primary cerebral lymphomas.
  • Among the 299 cases (54.2%) of NAD malignomas were 213 solid tumors including 71 anal carcinomas (= 33.5% of all NAD malignancies) and 85 hemoblastoses including 29 Hodgkin lymphomas (= 9.6% of all NAD malignancies).
  • Interestingly, only 1 of 8 primary cerebral lymphomas has been reported after 2001.
  • The number of pts with Hodgkin's lymphoma has increased constantly from 2000 to 2007.
  • Anal carcinomas and Hodgkin's lymphomas in particular were markedly more prevalent in our HIV-positive cohort compared to published reports of the general population.
  • The incidence of primary cerebral lymphomas seems to decrease, whereas the incidence of Hodgkin's lymphoma is increasing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963512.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Flinn IW, Byrd JC, Furman RR, Brown JR, Lin TS, Bello C, Giese NA, Yu AS: Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):3543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies.
  • The PI3K p110δ isoform is highly expressed in cells of hematopoietic origin and plays a key role in B cell maturation and function.
  • In vitro studies of 0.1 to 10 μM CAL-101 showed inhibition of pAKT expression and/or apoptotic effects against primary chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) cells and against a range of leukemia and lymphoma cell lines.
  • METHODS: In an ongoing phase 1 dose escalation study in sequential cohorts of 3 patients with relapsed/refractory CLL or select B-cell non-Hodgkin's lymphoma, CAL-101 is administered orally twice daily for 28 days per cycle.
  • Clinical response is evaluated according to NCI criteria at the end of Cycles 1 and 2 and every 2 cycles thereafter.
  • Two of 6 patients attained partial response and 4 have stable disease.
  • Partial responses were observed after 2 cycles of 50 mg in a patient with mantle cell lymphoma with 6 prior therapies, and after 1 cycle of 100 mg in a patient with follicular lymphoma with 6 prior therapies, including autologous stem cell transplant.
  • Disease specific cohort expansion will occur at the maximally tolerated dose, and patients with AML will be added.
  • CONCLUSIONS: Early results from a phase 1 study of the oral PI3K p110δ inhibitor CAL-101 show that it is well tolerated and has preliminary clinical activity in patients with B-cell malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961357.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Passalacqua R, Brighenti M, Naldi N, Potenzoni D, Monica B, Fumagalli M, Lazzarelli S, Caminiti C: Long-term effects of a program of bladder preservation using chemotherapy plus radiotherapy in muscle invasive bladder cancer (BC). Analysis of biologic predictive factors and health-related quality of life (QOL). J Clin Oncol; 2009 May 20;27(15_suppl):e16014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover we investigated whether p53, Ki67, bcl-2, c-erbB-2 protein expression predict the achievement of a complete response (CR).
  • At the response evaluation, pts with biopsy proven residual disease were considered incomplete responders (IR) and underwent immediate cystectomy.
  • Paraffin embedded blocks of the primary tumors were collected and Ki67, p53, bcl-2 and c-erbB-2 protein expression were evaluated in a blind fashion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962925.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Ready N, Potti A, Karaseva N, Orlov S, Luft A, Popovych O, Liu PY, Holmlund JT, Wood BA, Leopold L: AT-101 or placebo (P) with docetaxel (D) in second-line NSCLC with gene signature biomarker development. J Clin Oncol; 2009 May 20;27(15_suppl):3577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3577 Background: AT-101 inhibits the Bcl-2 protein family (Bcl-2, Bcl-xL, Mcl-1, Bcl-W) with broad preclinical activity including synergy with D.
  • A biomarker of AT-101 activity was developed by treating 55 NSCLC cell lines with AT-101 and using the corresponding gene expression data to identify a genomic predictor of sensitivity to AT-101.
  • Analysis of gene expression data by Bayesian regression revealed a robust 500 gene predictor of sensitivity to AT-101 that was cross validated in a leave one out analysis and in an independent cohort of 32 NSCLC cell lines.
  • CONCLUSIONS: In this phase II trial AT-101, an oral pan Bcl-2 family inhibitor, had favorable OS compared to placebo when combined with docetaxel in previously treated NSCLC and was well tolerated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961708.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Sola CB, Silva L, Saliba R, De Lima M, Giralt S, Qazilbash M, Champlin R, Khouri I, Popat U, Hosing C: Outcomes of autologous bone marrow transplantation in non-Hodgkin's lymphoma patients who failed peripheral blood stem cell mobilization. J Clin Oncol; 2009 May 20;27(15_suppl):7040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of autologous bone marrow transplantation in non-Hodgkin's lymphoma patients who failed peripheral blood stem cell mobilization.
  • : 7040 Background: Patients (pts) with relapsed/refractory non-Hodgkin's lymphoma (NHL) who fail to mobilize adequate peripheral blood stem cells (PBSC) often undergo bone marrow (BM) harvest for autologous transplantation.
  • Twelve pts (35%) had history of BM involvement with lymphoma.
  • At the time of stem cell mobilization 18 (50%) were in complete remission (CR), 13 (37%) were in partial remission (PR) and 5 (13%) had progressive disease (PD).
  • RESULTS: The median total nucleated cell dose and CD34+ cell dose harvested/kg were 3.72 x 10<sup>8</sup> (range 0.25-58.0) and 1.6 x 10<sup>6</sup> (range 0.03-5.8), respectively.
  • Causes of death were: disease progression/relapse in 15 (60%), secondary malignancy in 3 (12%), multiorgan failure in 5 (20%), and unknown in 2 (8%).
  • Non-myeloablative allogeneic transplantation may provide better outcomes with similar toxicity and needs to be further studied.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961403.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Tawfik O, Garimella R, Tancabelic J, Keighley J, Pinson D, Khan Q, Templeton K: Retrospective immunohistochemical study of VDR, RXR, Ki-67, and Bcl-2 expression in primary and metastatic osteosarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):e21516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective immunohistochemical study of VDR, RXR, Ki-67, and Bcl-2 expression in primary and metastatic osteosarcoma.
  • : e21516 Background: Osteosarcoma (OS) is a highly malignant tumor with a peak incidence in adolescents and young adults.
  • Patient's prognosis is limited to clinical parameters whereas molecular markers of tumor aggression are yet to be identified.
  • METHODS: Immunohistochemical analysis for VDR, RXR, Ki-67, and bcl-2 was performed on 87 OS specimens to evaluate differentiation, proliferation and apoptosis.
  • Clinical data including site of the primary tumor, presence or absence of metastasis, therapeutic regimens, and outcome were recorded.
  • Thirty-five OSs were conventional, 17 chondroblastic, 6 giant cell, 6 fibroblastic, 6 mixed, 3 telangiectatic, and 2 epithelioid variants.
  • None of the tumors studied was immunoreactive for bcl-2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963447.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Adamia S, Avet-Loiseau H, Amin SB, Moreau P, Minvielle SS, Treon S, Li C, Anderson KC, Munshi N: Clinical and biological significance of microRNA profiling in patients with myeloma. J Clin Oncol; 2009 May 20;27(15_suppl):8539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biological significance of microRNA profiling in patients with myeloma.
  • : 8539 MicroRNA, a small endogenous RNA regulating specific expressed gene function has been implicated in normal biological processes as well as in malignant transformation.
  • Here we have investigated the role of microRNAs in multiple myeloma (MM) biology, and their influence on prognosis and clinical outcome.
  • We evaluated profiles of 384 microRNAs in CD138+ MM cells from 79 patients with MM, 11 cell lines and 9 healthy donors using qRT-PCR based microRNA array.
  • We detected significant modulation of expression of 61 microRNAs in myeloma cells compared to normal plasma cells.
  • Group A clustered with MM cell lines, indicating more aggressive course of disease.
  • Within B group, second degree node, group B2, clustered with normal plasma cells indicating indolent course.
  • In group A miR585 and let-7f were upregulated 8-12 fold; in group B, all differentially expressed microRNAs were downregulated (p<0.001) compared to normal plasma cells.
  • These modulated miRNAs target critical signaling molecules such as HOX9, c-myc, Bcl-2, SHP1 and SHP2.
  • We further analyzed the effect of microRNA on clinical outcome.
  • Functional analysis by modulating miRNAs 585, 155 and let-7f showed change in levels of predicted genes with consequent biological effect on growth and apoptosis in MM cell line.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960934.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Pavlick AC, Ott P, Escalon J, Madden K, Yepes E, Staha J, Mendoza S, Gandhi A, Yee H, Liebes L: Survival of advanced melanoma patients with normal LDH treated with oblimersen, temozolomide, and nab-paclitaxel. J Clin Oncol; 2009 May 20;27(15_suppl):9080

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 9080 Background: Oblimersen (OBL), temozolomide (TMZ), and abraxane (ABX) act synergistically in preclinical studies with melanoma cell lines.
  • Bcl-2 antisense therapy in combination with dacarbazine was encouraging in advanced melanoma patients(pts) with normal LDH.
  • METHODS: Chemotherapy-naïve advanced melanoma pts (ECOG PS ≤ 2, baseline LDH ≤1.1 × ULN, measurable disease per RECIST) were enrolled on a phase I/II protocol.
  • Immunohistochemical (IHC) staining for Bcl-2, Bcl-XL, BAK and caspase 3 was performed in pre- and post-therapy tumor samples.
  • Disease sites included liver (6), other visceral sites (10), skin, subcutaneous tissue, and lymph nodes (2).
  • Shed cryptic epitopes correlated with clinical response versus disease progression.
  • Alteration of the tumor biology based on phenotypic changes in Bcl-2, Bcl-xL, BAK and caspase 3 correlated with response to treatment.
  • Biomarker studies support the rationale that Bcl-2 antisense therapy specifically impacts apoptotic signaling pathways in melanoma cells from metastatic tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Naqi N, Khatak J: Neutrophil toxicity and primary prophylaxis in diffuse large B cell lymphoma treated with R-CHOP. J Clin Oncol; 2009 May 20;27(15_suppl):e19548

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutrophil toxicity and primary prophylaxis in diffuse large B cell lymphoma treated with R-CHOP.
  • : e19548 Background: Three weekly R-CHOP therapy is regarded as standard treatment in advanced stage Diffuse Large B Cell Lymphoma (DLBCL) patients with low to intermediate-risk International prognostic index (IPI).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960978.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Kagoya Y, Sahara N, Matsunaga T, Uekusa T, Irie S, Hatanaka K: A Case of Primary Bone Marrow B-Cell Non Hodgkin's Lymphoma with Severe Thrombocytopenia: Case Report and A Review of the Literature. Indian J Hematol Blood Transfus; 2010 Sep;26(3):106-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Case of Primary Bone Marrow B-Cell Non Hodgkin's Lymphoma with Severe Thrombocytopenia: Case Report and A Review of the Literature.
  • Combined with immunophenotypic analysis, a diagnosis of primary bone marrow B-cell non-Hodgkin's lymphoma was made.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):780-6 [12428800.001]
  • [Cites] Mt Sinai J Med. 2003 Mar;70(2):133-8 [12634906.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):769-75 [15160954.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1163-72 [1694234.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):923-30 [9378552.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1549-57 [16327427.001]
  • [Cites] Haematologica. 2008 Mar;93(3):447-50 [18287133.001]
  • [Cites] Blood. 1989 Feb 15;73(3):787-91 [2644990.001]
  • [Cites] Cancer. 1980 Oct 15;46(8):1767-74 [6968620.001]
  • [Cites] Cancer. 1982 Mar 1;49(5):888-97 [6977408.001]
  • [Cites] Mayo Clin Proc. 1994 Jan;69(1):37-43 [8271848.001]
  • (PMID = 21886395.001).
  • [ISSN] 0974-0449
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3002093
  •  go-up   go-down


84. Kasimis B, Chang V, Gounder S, Gonzalez M, Finch-Cruz C, Blumenfrucht M, Srinivas S, Cogswell J, Morales E, Ahmed S: Prediction of survival by immunohistochemical stains (IHC) in stage D2 prostate cancer patients (pts): The importance of pTEN overexpression. J Clin Oncol; 2009 May 20;27(15_suppl):e16019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All pts has androgen deprivation for stage D2 disease and were followed at 3 month intervals.
  • METHODS: In an IRB approved study,42 pts had adequate tissue preserved between 1992 and 2006 and their charts were reviewed retrospectively.IHC stains to detect tumor expression of S6(ribosomal),p70s6,pTEN,AKT-1,BCL-1(Cyclin D1),VEGF,c-KIT,PDGFR-alpha and PDGFR-beta were performed by US Labs(Irvine,CA).All results were independently evaluated by two pathologists.Immunoreactivity was scored using a semiquantitative system combining intensity of staining(0-3+) and percentage of cells staining positive(0-3+).The total score was obtained by adding the scores for indensity and the percentage of positive cells,then averaging the resuts obtained by each reader.For the purpose of this study, stain intensity of 0-1+ was considered negative and the intensity of 2-3+ was considered positive.A Cox regression survival model for each stain was developed with variables known to predict survival :Gleason score,Hemoglobin(Hgb),Alkaline Phosphatase(Alk Phos),Prostate Specific Antigen(PSA),Lactate Dehydrogenase(LDH) levels.
  • CONCLUSIONS: In this small sample of pts, overexpression of S6,p70s6,AKT-1,BCL-1,VEGF,c-KIT,PDGFR-alpha and PDGFR-beta by IHC staining did not predict survival independently.The pTEN staining,however was strong predictor of survival in the multivariate analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962908.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. De La Mota J, Thomas B, Fengwei W, Micaily B, Yajue H, Hernandez E: Surgical and immunohistochemical (IC) risk factors for metastatic disease in stage IB1 cervical cancer (CC). J Clin Oncol; 2009 May 20;27(15_suppl):e16578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical and immunohistochemical (IC) risk factors for metastatic disease in stage IB1 cervical cancer (CC).
  • We sought to identify surgical and IC risk factors for metastatic disease.
  • RESULTS: Of the 35 patients identified, 25 (71%) had squamous cell, 9 (26%) adenocarcinoma, and 1 (3%) adenosquamous histology.
  • Immunohistochemical (IC) staining was performed on 29 cases (10 LVI, 4 positive LN) for bcl-2, p53, Ki-67.
  • No correlation was found with p53 or Bcl-2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961498.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Yi J, Kim S, Lee S, Park S, Ko Y, Choi J, Kim W: Clinical usefulness of PET/CT in initial staging and response evaluation of primary gastric lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19541

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical usefulness of PET/CT in initial staging and response evaluation of primary gastric lymphoma.
  • : e19541 Background: Positron emission tomography (PET)/computed tomography (CT) scan has a well-established role in the management of non-Hodgkin's lymphoma (NHL).
  • However, in case of the primary gastric lymphoma, which is the most frequent extranodal NHL, the role of PET/CT scan is still controversial.
  • METHODS: We retrospectively analyzed 42 patients with primary gastric lymphoma who underwent PET/CT scans; 32 patients with diffuse large B-cell lymphoma (DLBCL) and 10 patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) were analyzed.
  • After corresponding treatment, response was evaluated by conventional CT scans or PET/CT scans and endoscopy with biopsy Results: Nine patients were up-staged based on the results of their PET/CT scan compared to CT (7 DLBCL, 2 MALT lymphomas) while six patients were down-staged by the PET/CT scan.
  • Three patients with DLBCL, who showed an initially high SUVmax, died of disease progression.
  • All of these gastric lesions were grossly and pathologically benign lesions without evidence of lymphoma cells.
  • CONCLUSIONS: PET/CT scan can help staging patients with primary gastric lymphoma, and the maximum SUV has possibility to have prognostic value.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960998.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Nagai H, Kusumoto S, Sawada K, Yamaguchi M, Takayama N, Kinoshita T, Motoji T, Omachi K, Ogura M, Hotta T: Phase II study of cladribine with rituximab (R-2-CdA) therapy in patients with relapsed indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of cladribine with rituximab (R-2-CdA) therapy in patients with relapsed indolent B-cell non-Hodgkin's lymphoma.
  • : e19501 Background: Although cladribine has been reported to be one of active purine analogs against indolent B-cell non-Hodgkin's lymphoma (B-NHL), there are few reports of combination usage of cladribine and rituximab.
  • Histologies included 16 follicular lymphomas, 2 MALT lymphomas, 1 nodal marginal B cell lymphoma, and 1 lymphoplasmacytic lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960885.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Bower M, Syed N, Papoudou-Bai A, Stebbing J, Naresh K, Hatzimichael E, Powles S, Crook T: Methylation reversal in high-grade B lymphoma cell lines and novel epigenetic changes conserved between immunocompetent and HIV-positive hosts. J Clin Oncol; 2009 May 20;27(15_suppl):8585

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation reversal in high-grade B lymphoma cell lines and novel epigenetic changes conserved between immunocompetent and HIV-positive hosts.
  • : 8585 Background: Methylation-dependent transcriptional silencing is an important mechanism of tumour suppressor gene inactivation in neoplasia, including lymphoma.
  • METHODS: Pharmacological "unmasking" of transcriptionally silenced genes in B lymphoma cell lines was achieved using 5' deazacytidine ± Trichostatin A and subsequent analysis of mRNA levels on micro-array.
  • Candidate genes thus identified, were further analysed by qPCR, methylation-specific PCR (MSP) and bisulphite sequencing in B lymphoma cell lines and by MSP in clinical samples from sporadic (immunocompetent) (18 cases) and HIV-infected patients (14 cases).
  • Samples in both patient groups were diffuse large B cell lymphoma (DLBCL) and Burkitt's lymphoma (BL).
  • Additionally, we analysed 8 cases of marginal zone lymphoma (MZL) from the immunocompetent group.
  • RESULTS: We report the identification of 13 novel genes, not previously described in the literature, which are subject to methylation-dependent transcriptional silencing in high-grade lymphoma and whose expression can be reactivated by demethylating agents.
  • The frequency of methylation in individual genes varied from approximately 10% to 75% in specific lymphoma subtypes, but was in general similar in high grade lymphomas in immunocompetent and HIV-infected hosts.
  • CONCLUSIONS: Using pharmacological reversal of methylation, we have identified a number of genes, not previously implicated in human neoplasia, which are subject to transcriptional silencing in high-grade B lymphomas.
  • Detection of methylated DNA of one or more of these genes may have utility as biomarkers of clinical outcome in each patient group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962294.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Singh T, Amirtham U, Satheesh CT, Sajeevan KV, Jain A, Lakshmaiah KC, Babu KG, Lokanatha D: Primary B cell non-Hodgkin's lymphoma of tongue. Indian J Cancer; 2010 Jan-Mar;47(1):84-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary B cell non-Hodgkin's lymphoma of tongue.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Tongue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20071804.001).
  • [ISSN] 1998-4774
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  •  go-up   go-down


90. Briani C, Zambello R, Cavallaro T, Ferrari S, Lucchetta M, Pollanz S, Grisold W: Improvement of peripheral nervous system manifestations of B-cell non-Hodgkin's lymphoma after rituximab therapy. J Peripher Nerv Syst; 2009 Jun;14(2):146-8
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of peripheral nervous system manifestations of B-cell non-Hodgkin's lymphoma after rituximab therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / drug therapy. Peripheral Nervous System Diseases / drug therapy. Peripheral Nervous System Diseases / etiology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691537.001).
  • [ISSN] 1529-8027
  • [Journal-full-title] Journal of the peripheral nervous system : JPNS
  • [ISO-abbreviation] J. Peripher. Nerv. Syst.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


91. Matous J, Letzer J, Rosen P, Noga S, Fowler N, Smith S, Amin B, Shi H, Parasuraman S, Cheson B: Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study. J Clin Oncol; 2009 May 20;27(15_suppl):8550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study.
  • : 8550 Background: FL is an incurable indolent B-cell non-Hodgkin's lymphoma.
  • Bortezomib (Velcade, V) plus R was active and generally well tolerated in rel/ref FL [de Vos ASH 2006 Abs694], and bendamustine hydrochloride (Treanda, B) plus R has also shown activity in heavily pretreated FL [Robinson JCO 2008].
  • METHODS: Pts with relapsed FL with ≥4 prior doses of R (no prior V or B), ≥1 measurable tumor mass, no active central nervous system lymphoma, KPS ≥50%, adequate hematologic, renal and hepatic function, and no peripheral neuropathy ≥G2 were eligible.
  • B dose escalation continued based on cycle 1 dose-limiting toxicities (DLTs), defined as: treatment-related platelet count <25,000/mm<sup>3</sup> for >7 days or any platelet count <10,000/mm<sup>3</sup>; G4 neutropenia for >7 days; any treatment-related ≥G3 non-hematologic toxicity other than inadequately treated nausea, vomiting, or diarrhea; or any toxicity resulting in >1 week treatment delay.
  • RESULTS: Sixteen pts (4 at B 50 mg/m<sup>2</sup>, 6 each at B 70 and 90 mg/m<sup>2</sup>) with a median of 3 prior therapies (range 1-13; 31% prior stem-cell transplantation) have been treated (15 evaluable for DLT); median age was 54.5 (44-80) yrs.
  • Non-hematologic AEs ≥G3 in >1 pt were diarrhea (31%), fatigue (25%), vomiting (13%), and nausea (13%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960956.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Baum PR, Cerveny C, Gordon B, Nilsson C, Wiens J, Rafiq S, Lapalombella R, Muthusamy N, Byrd JC, Wahl A: Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma.
  • : 8571 Background: TRU-016, a single chain anti-CD37 Fc fusion molecule has been shown to display pro-apoptotic and Fc-dependent cellular cytotoxicity activities against primary CLL cells and NHL cell lines.
  • The pro-apoptotic signal generated by TRU-016 binding to CD37 on CLL cells has been shown to be caspase-independent and distinct from the signal generated by many other therapeutics including rituximab.
  • We have tested drug combinations using the mantle cell lymphoma line Rec-1 and diffuse large B-cell lymphoma line SU-DHL-6 in vitro and extended these results to in vivo settings using the follicular lymphoma cell line DOHH2 treated with the combination of TRU-016 and bendamustine.
  • METHODS: To determine TRU-016 interactions with the established therapeutics rituximab, doxorubicin, rapamycin, and bendamustine, drugs were tested alone or in combination with TRU-016 and the anti-proliferative effects on cell lines measured after 96 hours.
  • To determine if in vitro synergy could be recapitulated in vivo, SCID mice were implanted with DOHH2 cells and therapeutic treatment was initiated when tumor volumes reached 200 mm<sup>3</sup>.
  • This demonstrates that the in vitro synergy results were extendable to a more complex in vivo disease model.
  • CONCLUSIONS: TRU-016 in combination with rituximab, rapamycin, or bendamustine increases cell killing of NHL cells.
  • Furthermore, the combination of TRU-016 and bendamustine displayed greater in vivo anti-tumor activity than either agent alone against a follicular lymphoma tumor model.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961015.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Braun E, Katz D, Venugopal P, Larson M, Shammo J, Fung H, Gregory S: Safety analysis of radioimmunotherapy (RIT) in patients with relapsed or refractory low grade, follicular or transformed non-Hodgkin's lymphoma and mantle cell lymphoma based on age at time of therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e19529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety analysis of radioimmunotherapy (RIT) in patients with relapsed or refractory low grade, follicular or transformed non-Hodgkin's lymphoma and mantle cell lymphoma based on age at time of therapy.
  • : e19529 Background: Radioimmunotherapy is a therapeutic option for relapsed or refractory indolent, follicular and transformed non Hodgkin's lymphoma and mantle cell lymphoma.
  • Groups characteristics such as sex, type of RIT, presence of disease in bone marrow, FLIPI/IPI and use of G-CSF were noted.
  • CONCLUSIONS: RIT should be considered a safe therapeutic modality in patients with refractory or relapsed indolent, follicular, NHL, transformed and Mantle Cell lymphoma regardless of age.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960911.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Wiwanitkit V: Individuals with HGV-RNA are at high risk of B cell non-Hodgkin's lymphoma development. Asian Pac J Cancer Prev; 2005 Apr-Jun;6(2):215-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Individuals with HGV-RNA are at high risk of B cell non-Hodgkin's lymphoma development.
  • Lymphoma is a common hematological malignancy.
  • Hepatitis viruses, especially hepatitis B and hepatitis C, are known risk factors for development of non-Hodgkin lymphomas.
  • Whethere there is a correlation between infection and development of non-Hodgkin's lymphoma is of interest.
  • Therefore an appraisal of the prevalence of HGV RNA among patients with B cell non-Hodgkin's lymphoma comparing with healthy control subjects was performed.
  • According to the literature review, three reports covering 247 cases of non Hodgkin's lymphoma were recruited.
  • Of the three reports, only two had complete data on the prevalence in both patients with B cell non-Hodgkin's lymphoma and healthy control subjects andwere used for further metanalysis study, covering 178 cases and 355 healthy subjects.
  • According to this study, it can be seen that individuals who are HGV RNA positive may be at very high risk of B cell non-Hodgkin's lymphoma development.
  • [MeSH-major] GB virus C / pathogenicity. Hepatitis, Viral, Human / complications. Lymphoma, B-Cell / virology. Lymphoma, Non-Hodgkin / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101337.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / RNA, Viral
  • [Number-of-references] 9
  •  go-up   go-down


95. Ghazi AA, Attarian H, Attarian S, Abasahl A, Daryani E, Farasat E, Pourafkari M, Tirgari F, Ghazi SM, Kovacs K: Hypercalcemia and huge splenomegaly presenting in an elderly patient with B-cell non-Hodgkin's lymphoma: a case report. J Med Case Rep; 2010;4:330
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypercalcemia and huge splenomegaly presenting in an elderly patient with B-cell non-Hodgkin's lymphoma: a case report.
  • INTRODUCTION: Hypercalcemia is the major electrolyte abnormality in patients with malignant tumors.
  • It can be due to localized osteolytic hypercalcemia or elaboration of humoral substances such as parathyroid hormone-related protein from tumoral cells.
  • In hematological malignancies, a third mechanism of uncontrolled synthesis and secretion of 1-25(OH)2D3 from tumoral cells or neighboring macrophages may contribute to the problem.
  • However, hypercalcemia is quite unusual in patients with B-cell non-Hodgkin's lymphoma.
  • Microscopic evaluation revealed a malignant lymphoma.
  • High serum calcium is seen in only seven to eight percent of patients with B-cell non-Hodgkin's lymphoma, apparently due to different mechanisms.
  • Evaluation of serum parathyroid hormone-related protein and 1-25(OH)2D3 can be helpful in diagnosis and management.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20959010.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2974746
  •  go-up   go-down


96. Foschi D, Rizzi A, Corsi F, Trabucchi E, Corbellino M: Chylous ascites secondary to B-cell non Hodgkin's lymphoma in a patient with the acquired immune deficiency syndrome (AIDS). Dig Liver Dis; 2008 Jun;40(6):481-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chylous ascites secondary to B-cell non Hodgkin's lymphoma in a patient with the acquired immune deficiency syndrome (AIDS).
  • In the present article we describe a patient with AIDS and chylous ascites secondary to B-cell non Hodgkin's lymphoma.
  • The final pathology report was of diffuse, CD20-positive, CD3-negative, Epstein Barr Virus-negative, large B-Cell non Hodgkin's lymphoma.
  • Five months after the initial diagnosis of lymphoma, the patient relapsed and was treated with high-dose BEAM (carmustine, etoposide, cytosine, arabinoside, melphalan) chemotherapy followed by CD34 stem-cell transplantations salvage therapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Chylous Ascites / etiology. Lymphoma, AIDS-Related / complications. Lymphoma, B-Cell / complications

  • Genetic Alliance. consumer health - Chylous Ascites.
  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17997372.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


97. Heist RS, Fain J, Chinnasami B, Khan W, Molina J, Brainerd V, Leopold L, Lynch T: A phase I/II (P1/P2) study of AT-101 in combination with topotecan (T) in patients with relapsed or refractory small cell lung cancer (SCLC) after prior platinum-containing first-line chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):8106

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II (P1/P2) study of AT-101 in combination with topotecan (T) in patients with relapsed or refractory small cell lung cancer (SCLC) after prior platinum-containing first-line chemotherapy.
  • : 8106 Background: Bcl-2 family proteins are expressed in SCLC and are associated with chemotherapy resistance.
  • AT-101 is an oral, pan Bcl-2 family protein inhibitor (Bcl-2, Bcl-X<sub>L</sub>, Mcl-1, and Bcl-w) and potent inducer of proapoptotic proteins.
  • AT-101 has demonstrated activity in SCLC models, including those that express Mcl-1 and are resistant to other Bcl-2 inhibitors.
  • METHODS: Pts ≥18 years of age, PS 0-1, with relapsed or refractory SCLC after first line chemotherapy with measurable disease per RECIST were eligible.
  • The PR/SD/PD/NE rates were 17%/70%/9%/4% and 8%/54%/23%/15%, in cohorts A/B respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964282.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Dummer R, Eichmüller S, Gellrich S, Assaf C, Dreno B, Schiller M, Dereure O, Baudard M, Bagot M, Khammari A, Bleuzen P, Bataille V, Derbij A, Wiedemann N, Waterboer T, Lusky M, Acres B, Urosevic-Maiwald M: Phase II Clinical Trial of Intratumoral Application of TG1042 (Adenovirus-interferon-γ) in Patients With Advanced Cutaneous T-cell Lymphomas and Multilesional Cutaneous B-cell Lymphomas. Mol Ther; 2010 Jun;18(6):1244-1247

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II Clinical Trial of Intratumoral Application of TG1042 (Adenovirus-interferon-γ) in Patients With Advanced Cutaneous T-cell Lymphomas and Multilesional Cutaneous B-cell Lymphomas.
  • : Cutaneous lymphomas (CLs) are a heterogeneous group of lymphoproliferative disorders that are manageable by immunotherapy.
  • Twenty-one patients were enrolled in a prospective open-label, dose-escalation multicenter study evaluating the effects of repeated TG1042 [adenovirus-interferon (IFN)-γ] intralesional injections in patients with primary CLs, of which 18 were of T-cell and 3 of B-cell type.
  • Immune monitoring in the peripheral blood demonstrated systemic immune activation and the induction of antibodies against tumor antigens in some patients without clear association with clinical responses.
  • CLs, in particular B-cell lymphomas with high objective response rates, seem to be excellent targets for this type of immunotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178498.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Colovic N, Jurisic V, Terzic T, Atkinson HD, Colovic M: Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin's lymphoma. Arch Dermatol Res; 2009 Oct;301(9):689-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin's lymphoma.
  • The case of a 44-year-old man with a primary cutaneous large B-cell non-Hodgkin's lymphoma of the scalp is reported.
  • His mother died of gastric lymphoma and his sib brother is in a 20-year remission of T-cell lymphoma.
  • The histopathology and immunohistochemistry performed in April 2006 indicated a bcl-6+, MUM- and bcl-2-, primary cutaneous follicle center B-cell non-Hodgkin's lymphoma, with an aggressive transformation to a diffuse large B-cell lymphoma.
  • Bone marrow biopsy and CT chest, abdomen, and pelvis were negative for systemic lymphoma.
  • The patient had an excellent clinical and histological resolution following 8 cycles of rituximab and CHOP protocol immunochemotherapy, and remains in complete remission until now.
  • The protracted indolent phase of the disease, the familial history of lymphoma, the histological aggressive features and the patient's excellent response to immunochemotherapy all contribute to a very unusual manifestation of this disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antigens, Neoplasm / metabolism. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Immunotherapy. Injections, Intravenous. Male. Prednisone / therapeutic use. Proto-Oncogene Proteins c-bcl-2 / metabolism. Rituximab. Treatment Outcome. Vesicular Transport Proteins / metabolism. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19495780.001).
  • [ISSN] 1432-069X
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / BCL2L15 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / TRAPPC1 protein, human; 0 / Vesicular Transport Proteins; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


100. Doudican NA, Pennell R, Tu T, Liebes L, Pavlick A, Berman R, Shapiro R, Goldberg JD, Osman I, Orlow S: Effect of mebendazole on melanoma xenograft growth through targeting of bcl-2. J Clin Oncol; 2009 May 20;27(15_suppl):9075

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of mebendazole on melanoma xenograft growth through targeting of bcl-2.
  • : 9075 Background: Defects in apoptosis are thought to contribute to melanoma chemoresistance, making the anti-apoptotic protein Bcl-2 an attractive therapeutic target.
  • We identified mebendazole (MBZ), a microtubule binding agent, as an inducer of melanoma cytotoxicity via a Bcl-2 dependent mechanism in vitro (Mol Cancer Res, Aug 2008).
  • In the present study, we assessed the effect of MBZ on human melanoma tumor growth and progression in a mouse xenograft model and compared the ability of MBZ to inhibit growth of cultured melanoma cells to that of oblimersen (OBL), an antisense drug targeting Bcl-2.
  • Bcl-2 phosphorylation was determined by immunoblotting.
  • This reduction in volume was accompanied by a 46% decrease in proliferating cells and an 81% increase in apoptotic cells.
  • Orally administered MBZ treatment resulted in Bcl-2 phosphorylation in vivo, further confirming its mechanism of action.
  • MBZ inhibited growth of melanoma cells in culture more effectively than OBL with GI50 values of 0.32 uM and 7.45 uM, respectively.
  • A phase II clinical trial investigating MBZ's utility as adjuvant therapy in patients with stage IV, resected melanoma is planned.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962178.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement